👤 Liying Wang

🔍 Search 📋 Browse 🏷️ Tags ❤️ Favourites ➕ Add 🧪 BiometalDB 🧬 Extraction
4397
Articles
2763
Name variants
Also published as: Junli Wang, Xindi Wang, Junpeng Wang, Tingyu Wang, Guoqiang Wang, Yuxuan Wang, Hanzhi Wang, Zhi-Long Wang, Shanshan Wang, Wenfei Wang, Dengbin Wang, Yen-Sheng Wang, Chuanxin Wang, Zeyu Wang, Beibei Wang, Taicheng Wang, Xingguo Wang, Z P Wang, Yue-Min Wang, Chenghua Wang, Xianqiang Wang, Congrong Wang, Yanhai Wang, Du Wang, Xianzhe Wang, Zuoheng Wang, Yongyi Wang, Zhihui Wang, Yanhua Wang, Limeng Wang, H J Wang, Pei-Jian Wang, Yana Wang, Congrui Wang, Larry Wang, Yu-Zhuo Wang, Sihua Wang, Wanchun Wang, Jialin Wang, Xinying Wang, Shuguang Wang, Yinhuai Wang, Xiaobin Wang, Yuying Wang, Hebo Wang, Leli Wang, Jiayu Wang, Zhaojun Wang, Hai Wang, Si Wang, Re-Hua Wang, Xuping Wang, Bo Wang, Shubao Wang, Songjiao Wang, Hongjia Wang, Victoria Wang, Ling Wang, Jianjie Wang, Haining Wang, Dali Wang, Ji-Yang Wang, Cheng Wang, Weifan Wang, Yuanqiang Wang, Zhixiao Wang, Yaxian Wang, Zhigang Wang, Haochen Wang, Jia-Ying Wang, Shichao Wang, Ruosu Wang, N Wang, Haixing Wang, Guiqun Wang, Zhiting Wang, Dan Wang, Wangxia Wang, Jing-Long Wang, Yaqian Wang, Yafang Wang, Xing-Jun Wang, Dapeng Wang, Zhongyuan Wang, Junsheng Wang, Zhaohai Wang, He-Ping Wang, Minmin Wang, Wenzhou Wang, Zhaohui Wang, Yanfang Wang, Pengtao Wang, Leran Wang, Qianwen Wang, Hongkun Wang, Sa Wang, Y Alan Wang, Liyan Wang, Jou-Kou Wang, Mingda Wang, Chenfei Wang, Yuehan Wang, Simeng Wang, Yuhua Wang, Ruibin Wang, Haibo Wang, Ni Wang, Guoxiu Wang, Zhuangzhuang Wang, Yajie Wang, Zhixiang Wang, Sangui Wang, Xiantao Wang, Yan-Yang Wang, Mengjun Wang, Ruling Wang, Peihe Wang, Miao Wang, Zaihua Wang, Jun-Jie Wang, Mengyao Wang, Zhiyu Wang, Changzhen Wang, Xijun Wang, Chengjian Wang, Yiyi Wang, Mo Wang, Xiaolun Wang, Danan Wang, Fanchang Wang, Zilin Wang, Fanhua Wang, Supeng Perry Wang, Gavin Wang, Yi-Ying Wang, Yani Wang, Zhuowei Wang, Weiwei Wang, Haifeng Wang, Yi-Shiuan Wang, Yan-Chao Wang, Xiaotong Wang, Jia-Qi Wang, Yongliang Wang, Yongming Wang, Fengchong Wang, Jianyong Wang, Zeping Wang, Huaquan Wang, Xiaojia Wang, Tao Wang, Tianjun Wang, Siying Wang, Zhenze Wang, Zhijian Wang, Li Wang, Heming Wang, Jingtong Wang, Xuefei Wang, Yingqiao Wang, Xiao Qun Wang, Chun-Chieh Wang, Shuang-Xi Wang, Laiyuan Wang, Zhaoming Wang, Yinggui Wang, Qi-Jia Wang, Wen-Yan Wang, Mingming Wang, Peipei Wang, Chien-Hsun Wang, Qiuhong Wang, Monica Wang, Lexin Wang, Xiufen Wang, Yuehua Wang, Pingfeng Wang, Caiyan Wang, Weijie Wang, Yigang Wang, Jieyan Wang, Huiquan Wang, Chunsheng Wang, Yunhe Wang, Changtu Wang, Qingliang Wang, Guanghua Wang, Yongbin Wang, Zhaobo Wang, Minghui Wang, Junshi Wang, Jingyu Wang, Longsheng Wang, Fen Wang, Xianshu Wang, Jianwu Wang, Jun-Zhuo Wang, Zhixing Wang, Lei Wang, Yiyan Wang, Jinglin Wang, Jinhe Wang, Enhua Wang, Yuecong Wang, Xueying Wang, Jennifer T Wang, Xin-Hua Wang, Shijie Wang, Chun-Xia Wang, Yuanjiang Wang, Xiaojun Wang, Shunjun Wang, Chun-Juan Wang, M Wang, Jinfei Wang, Jinghuan Wang, Xuru Wang, Xiao-Lan Wang, Yu-Chen Wang, Zhi-Guo Wang, Luya Wang, Shuwei Wang, Pingchuan Wang, Qifan Wang, Xing-Quan Wang, Weiding Wang, Xuebin Wang, Yaling Wang, Chenyin Wang, Allen Wang, Liyuan Wang, Rong-Rong Wang, Wusan Wang, Wayseen Wang, Qianru Wang, Yi-Xin Wang, Hailin Wang, Yu-Hang Wang, Xuesong Wang, Haojie Wang, Wanxia Wang, Mengwen Wang, Hanping Wang, Yuhang Wang, Lueli Wang, Xinchang Wang, Oliver Wang, Shuge Wang, Jianhao Wang, Chong Wang, Kui Wang, Litao Wang, Zining Wang, Ming-Yang Wang, Hongxia Wang, Mingyi Wang, Hai Bo Wang, Bingnan Wang, Hongqian Wang, Jisheng Wang, Jiakun Wang, Maoju Wang, Xiaoqiu Wang, Dongyi Wang, Hai Yang Wang, Pengju Wang, Xiaofeng Wang, Huming Wang, Jian'an Wang, Qianrong Wang, Xiaowei Wang, Xiangkun Wang, Da Wang, Hongying Wang, Changying Wang, Changyu Wang, Xiaoqin Wang, Zhenxi Wang, Qiaoqiao Wang, Yu Tian Wang, Yupeng Wang, Xinli Wang, YueJiao Wang, Jian-chun Wang, Pengchao Wang, Xiao-Juan Wang, Siqing Wang, C Z Wang, Pengbo Wang, Baoli Wang, Yu-Zhe Wang, Gui-Qi Wang, Dazhi Wang, Yanwen Wang, Xingqin Wang, Shijin Wang, Wenming Wang, Fanxiong Wang, Tiansong Wang, Shuzhe Wang, Jie Wang, Jinling Wang, Yunfang Wang, Luyao Wang, Cun-Yu Wang, Zikang Wang, Quan-Ming Wang, Yingying Wang, Chia-Chuan Wang, Xintong Wang, Jufeng Wang, Xuejun Wang, Xiao-Qian Wang, Yijin Wang, Meng Yu Wang, Tianyi Wang, Chia-Lin Wang, Zhuo-Jue Wang, Yaohe Wang, Rong Wang, Hao-Hua Wang, Yong-Jun Wang, Xubo Wang, Dalong Wang, Yan-Ge Wang, Erika Y Wang, Ruixian Wang, Jin-Liang Wang, Shicung Wang, Saifei Wang, Jintao Wang, Zhenzhen Wang, Jiawei Wang, Beilei Wang, Huabo Wang, Huiyu Wang, Hongtao Wang, Chengjun Wang, Guo-Du Wang, Taoxia Wang, Zitao Wang, Jingwen Wang, Yibin Wang, Long Wang, Xinjing Wang, Qunzhi Wang, Liangliang Wang, Bangchen Wang, Yu-Fen Wang, Shibin Wang, Congcong Wang, Xiong Wang, Zhiren Wang, Xiaozhu Wang, Hong-Xia Wang, Qingyong Wang, Tianying Wang, Tammy C Wang, Huijie Wang, Tiansheng Wang, Mengzhao Wang, Jianshu Wang, Xinlong Wang, Benzhong Wang, Zhipeng Wang, Kaijie Wang, Xiaomin Wang, Peijun Wang, Zhiqiang Wang, Jundong Wang, Zheng Wang, Yueze Wang, Sujuan Wang, Qing-Yun Wang, Xiaoqing Wang, Zongqi Wang, Zhicun Wang, Fudi Wang, Seok Mui Wang, Wanbing Wang, Kejun Wang, Nanping Wang, Mingyang Wang, Wenxia Wang, Yaru Wang, Zikun Wang, Shidong Wang, Bei Bei Wang, Yu-Hui Wang, Rui Wang, Yige Wang, Tongxin Wang, Xiaohua Wang, Changjing Wang, Xingjin Wang, Bingjie Wang, Shaoyu Wang, Hui-Hui Wang, Zhenyu Wang, Baoying Wang, Yang-Yang Wang, Shi-Yao Wang, Lifei Wang, Fangfang Wang, Zhimei Wang, Kunpeng Wang, Binglong Wang, Daijun Wang, Qinghang Wang, Zi Wang, Shushu Wang, QingDong Wang, Qing K Wang, Fuhua Wang, Yanni Wang, Jianle Wang, Wenyan Wang, Jinning Wang, Ziqi Wang, Wei-Qi Wang, Yaolou Wang, Haoming Wang, Jian-Wei Wang, Tian Wang, Peixi Wang, Iris X Wang, Tongxia Wang, Mei-Xia Wang, Haiying Wang, Tielin Wang, Hongze Wang, Chung-Hsi Wang, Peiyao Wang, Linli Wang, Guanru Wang, Yuzhong Wang, Yunhan Wang, Jianan Wang, Menglong Wang, Yingxue Wang, Jiayi Wang, Dingxiang Wang, Ting Wang, Fenglin Wang, Jianqun Wang, Ran Wang, Kuan Hong Wang, Liusong Wang, Wen-Der Wang, Yixuan Wang, Feng Wang, Kaicen Wang, Eryao Wang, Yulei Wang, Huaibing Wang, Zhongzhi Wang, Jinrong Wang, Sujie Wang, Xiaozhong Wang, Xiao-Pei Wang, Li-Na Wang, H X Wang, Linjie Wang, Zhaosong Wang, Yafen Wang, Chuan-Wen Wang, Xiaoning Wang, Li-Xin Wang, Silas L Wang, Baocheng Wang, Hongyi Wang, Zhi-Xiao Wang, Shengjie Wang, Zhi-Hao Wang, Yaokun Wang, Shao-Kang Wang, Qunxian Wang, Jianghui Wang, Zhao Wang, Di Wang, Jianzhi Wang, Ruijing Wang, Ling Jie Wang, Qingshi Wang, Jianye Wang, Yuqiang Wang, Kangling Wang, Anxin Wang, Shengli Wang, Zhulin Wang, Hua-Wei Wang, Yiwen Wang, Yang Wang, Hanqi Wang, Changwei Wang, Honglei Wang, Yi Lei Wang, Wenkang Wang, Junjie Wang, Yazhou Wang, Peng-Cheng Wang, Chenzi Wang, Anqi Wang, Yuemiao Wang, Xuelin Wang, Rujie Wang, Dongyan Wang, Yuxue Wang, Wengong Wang, Qigui Wang, Junqing Wang, Ruhan Wang, Xinye Wang, Huihui Wang, Gengsheng Wang, Mark Wang, Zhidong Wang, Mengmeng Wang, Yuwen Wang, Liang Wang, Huaxiang Wang, Fangjun Wang, Huixia Wang, Haijiao Wang, Hong-Hui Wang, Yi-Shan Wang, Yunchao Wang, Junjun Wang, Binghai Wang, Xinguo Wang, Jun-Sing Wang, Lingzhi Wang, Yuexiang Wang, Hong-Gang Wang, Yen-Feng Wang, Xidi Wang, Jiawen Wang, Liangfu Wang, Lifeng Wang, Shihan Wang, Wentian Wang, Sa A Wang, Lee-Kai Wang, Yu-Wei Wang, Zumin Wang, Shau-Chun Wang, Jianjiao Wang, Tian-Tian Wang, Jiantao Wang, Edward Wang, Jianbo Wang, Qingfeng Wang, Wenran Wang, Xiaolin Wang, Fenghua Wang, Rongjia Wang, Shiqiang Wang, Caixia Wang, Guihu Wang, Xindong Wang, Wenxiu Wang, Xueguo Wang, YiLi Wang, Aizhong Wang, Qiqi Wang, Chengcheng Wang, D Wang, L Wang, Jianhua Wang, Qiuling Wang, Shaolian Wang, Wen-Qing Wang, Wenqing Wang, Yuchuan Wang, Guangdi Wang, Yiquan Wang, Huimei Wang, Genghao Wang, Zun Wang, Miranda C Wang, Annette Wang, Chi-Ping Wang, Hanmin Wang, Zhaoxi Wang, Shifeng Wang, Runze Wang, Mangju Wang, Junjiang Wang, Dong D Wang, Xiu-Ping Wang, Haijiu Wang, Linghuan Wang, Yiying Wang, Renqian Wang, Nana Wang, Xiangdong Wang, Shiyin Wang, Chaoyi Wang, Menghan Wang, Shuyue Wang, Yongmei Wang, Nanbu Wang, Lihua Wang, Hongyue Wang, Jianli Wang, Chunli Wang, Minghua Wang, Junkai Wang, Chenguang Wang, Siyue Wang, Jun Wang, Shu-Song Wang, Bingyan Wang, Qingping Wang, Zhong-Yu Wang, Fei-Fei Wang, Jennifer E Wang, Z-Y Wang, Dongxia Wang, Dang Wang, Zi-Hao Wang, Rihua Wang, Jutao Wang, Yanzhe Wang, Guohao Wang, Liming Wang, Yishu Wang, Xuemin Wang, Xianfeng Wang, Zixu Wang, Jingfan Wang, Guang-Jie Wang, Guixue Wang, Jiaojiao Wang, Yaxin Wang, Haibing Wang, Weizhong Wang, Hairong Wang, Hai-Jun Wang, Mingji Wang, Yongrui Wang, Huizhi Wang, Longfei Wang, Chongmin Wang, Jingyang Wang, Zhong-Ping Wang, Huanhuan Wang, Baisong Wang, Xiaohui Wang, Fengyang Wang, Wanliang Wang, Ziqiang Wang, Chuan Wang, Jeffrey Wang, Ying-Zi Wang, Ziwei Wang, Xian Wang, Hanyu Wang, Qiming Wang, Dedong Wang, Fengying Wang, Xiaoya Wang, Zhenhua Wang, Yanchun Wang, Keming Wang, Zi-Yi Wang, Dezhong Wang, Jingying Wang, Shouli Wang, Lan-lan Wang, Weiyu Wang, Yuhuai Wang, Jun Yi Wang, Wenying Wang, Xue-Feng Wang, Xing-Lei Wang, Yuehong Wang, Pengyu Wang, Yihe Wang, Guodong Wang, Weijian Wang, Wu-Wei Wang, Y Wang, Ruonan Wang, Jianbing Wang, Mian Wang, Dennis Qing Wang, Nannan Wang, Zuo Wang, Christine Wang, Ruixin Wang, Yaxiong Wang, Siwei Wang, Yuanzhen Wang, Wen-Chang Wang, Haijing Wang, X Wang, Melissa T Wang, Haixia Wang, Qianghu Wang, Hongsheng Wang, Xiurong Wang, Shaowei Wang, Shuo Wang, Zengtao Wang, Yun-Xing Wang, Songtao Wang, Mei Wang, Mengyun Wang, Qingming Wang, Ke-Feng Wang, Zhihao Wang, Haoqi Wang, X E Wang, Xin-Shang Wang, Dongmei Wang, Lingli Wang, Huai-Zhou Wang, Hua Wang, Kunzheng Wang, Mao-Xin Wang, Jingzhou Wang, Jiaqi Wang, Xingbang Wang, Wence Wang, Yongdi Wang, Xin-Qun Wang, Guoyi Wang, Jian-Guo Wang, Jiafu Wang, Pin Wang, Libo Wang, Junling Wang, J Z Wang, Haozhou Wang, Jing Wang, Hezhi Wang, T Q Wang, Xi-Hong Wang, Yuanfan Wang, Endi Wang, Hua-Qin Wang, Jeremy Wang, Songping Wang, Suyun Wang, Jiqing Wang, Shu-Ling Wang, Jennifer X Wang, Lily Wang, Yin-Hu Wang, Jen-Chywan Wang, Qingqing Wang, Shuangyuan Wang, Haihong Wang, Luyun Wang, Yake Wang, Ya-Nan Wang, Weicheng Wang, Jianxiang Wang, Zihua Wang, Lin Wang, Fu-Sheng Wang, Zongbao Wang, Tong-Hong Wang, Xianze Wang, Ting-Ting Wang, Haibin Wang, Xin-Yue Wang, Zhi-Gang Wang, Ziying Wang, Shukang Wang, Wen-Jun Wang, Delin Wang, Yating Wang, Xuehao Wang, Yefu Wang, Yi-Ning Wang, Cheng-zhang Wang, Jing J Wang, Xinglong Wang, Yanqing Wang, Tongyao Wang, Dongyang Wang, Deqi Wang, Qiao Wang, Alice Wang, Yunzhi Wang, Dayong Wang, Renxi Wang, Yeh-Han Wang, Mingya Wang, Longxiang Wang, Hualin Wang, Hailei Wang, Ao Wang, Wanyu Wang, Jiale Wang, Qiangcheng Wang, Huishan Wang, Yunqiong Wang, Xudong Wang, Xifu Wang, Wen-Xuan Wang, Dao Wen Wang, Zhi-Wei Wang, Xingchen Wang, Yanyang Wang, Yutao Wang, Huizhen Wang, Hu WANG, Y P Wang, Wen Wang, Qingsong Wang, Baofeng Wang, Ruo-Ran Wang, Yaobin Wang, Changliang Wang, Pintian Wang, Dai Wang, Su-Guo Wang, Ruting Wang, Fengzhen Wang, Qinrong Wang, HuiYue Wang, Baosen Wang, Shuhe Wang, Yifei Wang, Jiun-Ling Wang, Junhui Wang, Guangzhi Wang, Qijia Wang, Yushe Wang, Jinlong Wang, Zhouguang Wang, Huiyao Wang, Shuxin Wang, Yingyi Wang, Jing-Yi Wang, Yongxiang Wang, Zhi Wang, Dehao Wang, Yi-sheng Wang, Jiazhi Wang, Yunfei Wang, Mingjin Wang, Yaozhi Wang, Jinyu Wang, Jinmeng Wang, LiLi Wang, Shuai Wang, Yan Wang, Jun Kit Wang, Cui Wang, Zhan Wang, Dong-Jie Wang, Yangyang Wang, Xiangguo Wang, Runuo Wang, Ruimin Wang, Pengpu Wang, Nuan Wang, Guangyan Wang, Xin-Liang Wang, Minxiu Wang, Ruifang Wang, Hui Wang, Hongda Wang, Xiyan Wang, Jinxia Wang, Xinchen Wang, Haihua Wang, Delong Wang, Yayu Wang, Xue-Hua Wang, Xin-Peng Wang, Changqian Wang, Bei Wang, Ya-Han Wang, Chih-Liang Wang, P N Wang, Xiaoqian Wang, Xianshi Wang, Zhiruo Wang, Xueding Wang, Renxiao Wang, Yi-Ming Wang, Tianqi Wang, Ledan Wang, Rongyun Wang, Gan Wang, Qinqin Wang, Yuxiang Wang, Feimiao Wang, Mengyuan Wang, Chaofan Wang, Linshuang Wang, Yanhui Wang, Zhenglong Wang, Zongkui Wang, Zhenwei Wang, Xiyue Wang, Yi Fan Wang, Xiao-Ai Wang, Po-Jen Wang, Xinyang Wang, Linying Wang, Fa-Kai Wang, Yimeng Wang, Dong-Mei Wang, Anli Wang, Hui-Li Wang, Jianqing Wang, Honglun Wang, Wei-Feng Wang, Kaihao Wang, Jialing Wang, Shuren Wang, Cui-Fang Wang, Wenqi Wang, Peilin Wang, Wen-Fei Wang, Guang-Rui Wang, T Wang, Weiqing Wang, Ciyang Wang, Biao Wang, Kaihe Wang, Jieh-Neng Wang, Tony Wang, Yuehu Wang, Zhicheng Wang, Tongtong Wang, Zi Xuan Wang, Yingtai Wang, Xin-Xin Wang, Chu Wang, Tianhao Wang, Shukui Wang, Ching C Wang, Yulin Wang, Chunyang Wang, Yeqi Wang, Yinbo Wang, Kongyan Wang, Weiling Wang, Linxuan Wang, Shengya Wang, Yaqi Wang, Huating Wang, Aiting Wang, Ya Xing Wang, Daoping Wang, Shasha Wang, Wei-Lien Wang, Quanli Wang, Yanru Wang, L M Wang, Bijue Wang, H Wang, Jipeng Wang, Xiaoxia Wang, Shuu-Jiun Wang, Baitao Wang, Haimeng Wang, Chung-Hsing Wang, Weining Wang, M Y Wang, Wenwen Wang, Zhongsu Wang, Xiaochen Wang, Ligang Wang, Shaohsu Wang, Bing Qing Wang, Jiangbin Wang, Yajun Wang, Chunting Wang, Hemei Wang, En-hua Wang, H-Y Wang, Zixi Wang, Wenjing Wang, Haikun Wang, Ruxin Wang, Jianru Wang, Yongqiang Wang, Ouchen Wang, Jianyu Wang, Shen Wang, Yixi Wang, Zhi-Hong Wang, Li Dong Wang, Zhou-Ping Wang, Wen-Yong Wang, Meng-Lan Wang, Xiaojie Wang, Leying Wang, Yi-Zhen Wang, Y Y Wang, Jianlin Wang, Guoqing Wang, Jiani Wang, Guan-song Wang, You Wang, Xiangding Wang, Ke Wang, Wendong Wang, Yue Wang, Zhe Wang, K Wang, Zhuo Wang, Su'e Wang, Cangyu Wang, Erfei Wang, Xiaoming Wang, Aijun Wang, Xiaoye Wang, Jun-Sheng Wang, Wenxiang Wang, Yanjun Wang, Qiangqiang Wang, Yachun Wang, Haitao Wang, Tiancheng Wang, Gangyang Wang, Jianmin Wang, Jiabo Wang, Yijing Wang, Mengzhi Wang, Yinuo Wang, Zhou Wang, Guiying Wang, Xuezheng Wang, Shan Wang, Aoli Wang, Fuqiang Wang, Yawei Wang, Xianxing Wang, Ya-Long Wang, Yuyang Wang, Dong Hao Wang, Y-S Wang, Zelin Wang, Liqun Wang, Cunyi Wang, Qian-Zhu Wang, Yinan Wang, Panfeng Wang, Guangwen Wang, J Q Wang, Guang Wang, Yu-Ping Wang, John Wang, Jiaping Wang, Zhisheng Wang, Xuan-Ren Wang, Xiaowu Wang, Zhengyu Wang, Baowei Wang, Zhijun Wang, Zhong-Hao Wang, Fengzhong Wang, Jin-Da Wang, Zhaoqing Wang, Yuanbo Wang, Haixin Wang, Yaping Wang, Lixiu Wang, Mingxia Wang, Neng Wang, Guozheng Wang, Yan-Feng Wang, Huafei Wang, Yuhan Wang, Xingxing Wang, Wenhe Wang, Xing-Huan Wang, Xiansong Wang, Yishan Wang, Ruming Wang, Ya Qi Wang, Yueying Wang, Chunle Wang, Shihua Wang, W Wang, Hengjun Wang, Meihui Wang, Huanyu Wang, Ruinan Wang, Qiwei Wang, Zhong Wang, Shiyao Wang, Jian-Zhi Wang, Ruimeng Wang, Jinxiang Wang, Jinsong Wang, Bin-Xue Wang, Fuwen Wang, Yiou Wang, Shifa Wang, Yin Wang, Yanzhu Wang, Jia Bin Wang, Siyang Wang, Zhanggui Wang, Yueting Wang, Qingyu Wang, Qianqian Wang, Xiu-Lian Wang, Fengling Wang, Chenxi Wang, Cheng An Wang, Yipeng Wang, Weipeng Wang, Zechen Wang, Shuaiqin Wang, Xueqian Wang, Chan Wang, Guohang Wang, Cai-Yun Wang, Jiang Wang, Huei Wang, Yufeng Wang, Heng Wang, Qing-Liang Wang, Chuang Wang, Xiaofang Wang, Hao-Ching Wang, Junying Wang, Jianwei Wang, Jinhai Wang, Hanchao Wang, Penglai Wang, I-Ching Wang, S L Wang, Tianhu Wang, Sheng-Min Wang, Pan-Pan Wang, Duan Wang, Xuqiao Wang, Minghuan Wang, Wei-Wei Wang, Xiaojian Wang, Shuping Wang, Jinfu Wang, Biqi Wang, Zhenguo Wang, Fangyan Wang, Sainan Wang, Peijuan Wang, Pei-Yu Wang, Yuyan Wang, Fuxin Wang, Ji M Wang, Yange Wang, Yali Wang, Wenhui Wang, Leishen Wang, Lichan Wang, Xianna Wang, Wenbin Wang, Kenan Wang, Chih-Yuan Wang, Yanlei Wang, Ju Wang, Yanliang Wang, Keqing Wang, Bangshing Wang, Dayan Wang, Yongsheng Wang, Dinghui Wang, Zheyue Wang, Xinke Wang, Daqing Wang, Yan Ming Wang, He-Ling Wang, Shengyao Wang, Jiwen Wang, Xizhi Wang, Luxiang Wang, Dandan Wang, RongRong Wang, Heng-Cai Wang, Jindan Wang, Xiaoding Wang, Yumeng Wang, Heling Wang, Xiao-Yun Wang, Meiding Wang, Zhilun Wang, Guo-hong Wang, Na Wang, Yanli Wang, Fubing Wang, Feixiang Wang, Zhiyuan Wang, Yi-Cheng Wang, Zhengwei Wang, Wenyuan Wang, Yu-Ying Wang, Jianqin Wang, Sijia Wang, Chuansen Wang, Huawei Wang, Kaiyan Wang, Qingyuan Wang, Yujia Wang, Lian Wang, Junrui Wang, Chao-Yung Wang, Zehao Wang, Ruixue Wang, Minjun Wang, Jin Wang, Xiaoxiao Wang, Jun-Feng Wang, Binquan Wang, Shuxia Wang, Donggen Wang, Deming Wang, Chenggang Wang, Chuduan Wang, Haichuan Wang, Catherine Ruiyi Wang, Hai-Feng Wang, Anthony Z Wang, Guanghui Wang, Jiahao Wang, Xiaosong Wang, Zijue Wang, Wenbo Wang, M-J Wang, Yu Wang, Yingping Wang, Zhengbing Wang, G Q Wang, Mengjing Wang, Zhendong Wang, Kailu Wang, Jinfeng Wang, Zhiguo Wang, Yusha Wang, Jianmei Wang, Kun Wang, Lihong Wang, Haoxin Wang, Haowei Wang, Ziqing Wang, Aihua Wang, Yuanyong Wang, Sanwang Wang, Doudou Wang, Hao-Yu Wang, Peirong Wang, Wenting Wang, Yibing Wang, He Wang, Jia-Peng Wang, Shixin Wang, En-bo Wang, Dong-Dong Wang, Hualing Wang, Hongyan Wang, Shaoying Wang, Yingjie Wang, Tianqing Wang, Guo-Hua Wang, Yongfei Wang, Lijing Wang, Hongli Wang, Zixian Wang, Niansong Wang, Liangxu Wang, Xinrong Wang, X-T Wang, Zhenning Wang, Dake Wang, Yu-Ting Wang, Zonggui Wang, Daping Wang, Joy Wang, Chenji Wang, Jingmin Wang, Yuyin Wang, Jin-Cheng Wang, Jiangbo Wang, Huiyang Wang, Chi Chiu Wang, He-Cheng Wang, Zhongjing Wang, Weina Wang, Qiaohong Wang, Qintao Wang, Jenny Y Wang, Zheyi Wang, Robert Yl Wang, Zhaotong Wang, Ya Wang, Fangyu Wang, Haobin Wang, Tianyuan Wang, Xinrui Wang, Zhehao Wang, Yihan Wang, Chuan-Jiang Wang, Jianjun Wang, Yongfeng Wang, Gaofu Wang, Ying-Piao Wang, Jingwei Wang, Mengjiao Wang, Chuyao Wang, Yanping Wang, Xinchun Wang, Shu Wang, Guibin Wang, Hong-Ying Wang, Linping Wang, Yugang Wang, Xinru Wang, Fengyun Wang, Heyong Wang, Ziping Wang, Yuegang Wang, Xiangyu Wang, Haoran Wang, Xiaomei Wang, Fang Wang, Lina Wang, Guowen Wang, Liyun Wang, Qingshui Wang, Baoyun Wang, Li-Juan Wang, Tongsong Wang, Jingyun Wang, Huiguo Wang, Zhibo Wang, Lou-Pin Wang, Renjun Wang, Huiting Wang, Junfeng Wang, Zihan Wang, Linhua Wang, Zhiji Wang, Fubao Wang, Eunice S Wang, Xiaojuan Wang, Yuewei Wang, Shuang Wang, Ruey-Yun Wang, Xiaoling Wang, Weihua Wang, Yanggan Wang, Jia Wang, Chaoqun Wang, Xiao-liang Wang, Manli Wang, Yongkang Wang, Huiwen Wang, Ting Chen Wang, Yixian Wang, Xinlin Wang, Shuya Wang, Bochu Wang, Kehao Wang, Sasa Wang, Mengshi Wang, Qiu-Ling Wang, Chengshuo Wang, Mengru Wang, Yiwei Wang, Xueyun Wang, Yijun Wang, Haomin Wang, Meng C Wang, Mengxiao Wang, Huan-You Wang, Jingheng Wang, Carol A Wang, Benjamin H Wang, Penglong Wang, Pei-Wen Wang, Jian-Long Wang, Wang Wang, Jinhui Wang, Yuanqing Wang, Jacob E Wang, Jian-Xiong Wang, Wenyu Wang, Chengze Wang, Hongmei Wang, Fengqiang Wang, Zijun Wang, Shaochun Wang, Qinwen Wang, Ruicheng Wang, Aixian Wang, Yanling Wang, Lu-Lu Wang, Linyuan Wang, Yeming Wang, Ye Wang, Tian-Yi Wang, Zhichao Wang, Dangfeng Wang, Jiucun Wang, Guo-Liang Wang, Guandi Wang, Zhuo-Xin Wang, Aili Wang, Fengliang Wang, Yingzi Wang, Lirong Wang, Xuekai Wang, Wei-En Wang, Jing-Xian Wang, Hesuiyuan Wang, Yuexin Wang, Suzhen Wang, Luping Wang, Xiuyu Wang, Zicheng Wang, Jiliang Wang, Rikang Wang, Xue Wang, Shudan Wang, Chun Wang, Hongxin Wang, Chenglong Wang, Junxiao Wang, Zhiqing Wang, Shawn Wang, Shunran Wang, Tiantian Wang, Youhua Wang, Xiao-Hui Wang, Qing-Yan Wang, Hanying Wang, Qiuping Wang, Yongzhong Wang, Jin-Xia Wang, Xiao-Tong Wang, Shun Wang, Xiaoqun Wang, Ching-Jen Wang, Xin Wang, Hanbin Wang, Yingwen Wang, Jia Bei Wang, Xiaodan Wang, Wenhan Wang, Jia-Yu Wang, Xiaozhi Wang, Xinkun Wang, Jinhao Wang, KeShan Wang, Shengdong Wang, Jinzhu Wang, Lihui Wang, Bicheng Wang, Chao-Jun Wang, Shaoyi Wang, Yajing Wang, Qing-Bin Wang, Feiyan Wang, Geng Wang, Chen Wang, Zhimin Wang, Cenxuan Wang, Wenjun Wang, Chuan-Chao Wang, Zexin Wang, Shu-Huei Wang, Yonggang Wang, Zhaoyu Wang, Xiaochuan Wang, Chuan-Hui Wang, Junshuang Wang, X F Wang, Li-Ting Wang, Chenxin Wang, Qiao-Ping Wang, Jingqi Wang, Xiongjun Wang, Shuang-Shuang Wang, Xu Wang, Houchun Wang, Yaodong Wang, Lujuan Wang, Jilin Wang, Peichang Wang, Keyun Wang, Ruixuan Wang, Zhangying Wang, Lianyong Wang, Dongyu Wang, Xinghui Wang, Binghan Wang, Guanduo Wang, Xian-e Wang, Guimin Wang, Xiaomeng Wang, Yuh-Hwa Wang, Jinru Wang, Mingyu Wang, Binbin Wang, Chaokui Wang, Linhui Wang, Youzhi Wang, Zhenqian Wang, Jialiang Wang, Sufang Wang, Haiyan Wang, Yankun Wang, Yingbo Wang, Zilong Wang, Xiao-Qun Wang, Lin-Fa Wang, Wenhao Wang, P Wang, Rui-Hong Wang, Xiao-jian WANG, Pei Chang Wang, Zhengkun Wang, Vivian Wang, Ying Wang, Zihuan Wang, Peiwen Wang, Chao Wang, Da-Zhi Wang, He-Tong Wang, Mofei Wang, Zezhou Wang, Liyong Wang, Bruce Wang, Hao-Tian Wang, Jin-Juan Wang, Yucheng Wang, Yong-Gang Wang, Saili Wang, Xiuwen Wang, Ruiquan Wang, Xinmei Wang, Zhezhi Wang, Xiao-Jie Wang, H Y Wang, Li-Dong Wang, Duanyang Wang, Kaiting Wang, Yikang Wang, Yichen Wang, Ting-Chen Wang, Meixia Wang, ZhenXue Wang, Juan Wang, Shouling Wang, Lan Wang, Li Chun Wang, Xingxin Wang, Ruibing Wang, Xue-Ying Wang, Bi-Dar Wang, Jiayang Wang, Suxia Wang, Yumin Wang, Qing Jun Wang, Xinbo Wang, Youli Wang, Yi-Ni Wang, Xinran Wang, Lixian Wang, Kan Wang, Ruiming Wang, Qing-Yuan Wang, Kai-Kun Wang, Yaoxian Wang, Qing-Jin Wang, Junmei Wang, Xin Wei Wang, J P Wang, Xufei Wang, Yuqin Wang, Handong Wang, Li-San Wang, Guoling Wang, Wenrui Wang, Zhongwei Wang, Shi-Han Wang, Ruoxi Wang, Huiping Wang, Mu Wang, Weihong Wang, Minzhou Wang, Yakun Wang, Da-Cheng Wang, Pengjie Wang, Qihua Wang, Ji-Nuo Wang, Deshou Wang, Xiaowen Wang, Yaochun Wang, Qihao Wang, Ruiying Wang, Tiange Wang, Xi Wang, Yindan Wang, Lixin Wang, Zhaofeng Wang, Guixin Wang, Erming Wang, Haoyu Wang, Kexin Wang, Yiqiao Wang, Qi-Qi Wang, Shuiyun Wang, Xi-Rui Wang, Cai-Hong Wang, Zhizheng Wang, Mingxun Wang, Liangli Wang, Theodore Wang, Alexander Wang, Huayang Wang, Yinyin Wang, Shuzhong Wang, Tingting Wang, Jiao Wang, Wenxian Wang, Jianghua Wang, Furong Wang, Shijun Wang, Le Wang, Guihua Wang, Xiaokun Wang, Xia Wang, Jiabei Wang, Guoying Wang, Zeyuan Wang, Jue Wang, Jin-E Wang, Jingru Wang, Chun-Li Wang, Xiaole Wang, Ermao Wang, Lanlan Wang, Ye-Ran Wang, Hao Wang, Xv Wang, Shikang Wang, Yufei Wang, Siyi Wang, Xiujuan Wang, Qinyun Wang, Xiangwei Wang, Jian-Hong Wang, David Q-H Wang, Chunjuan Wang, Weiyan Wang, Jia-Liang Wang, Yanxing Wang, Sheri Wang, Chenwei Wang, Haoping Wang, Sheng-Quan Wang, Xiangrong Wang, Xiao-Yi Wang, Huan Wang, Zhitao Wang, Xinyan Wang, J Wang, Kaixi Wang, Huihua Wang, Renwei Wang, Xiaoliang Wang, Xiao-Lin Wang, Tian-Lu Wang, Jiou Wang, Weiqin Wang, Jiamin Wang, Dennis Wang, Ji-Yao Wang, Pingping Wang, Jinyang Wang, Chen-Cen Wang, Chien-Wei Wang, Daolong Wang, Rong-Tsorng Wang, Yuwei Wang, Guo-Ping Wang, Zhentang Wang, F Wang, Xueju Wang, Saisai Wang, Zhehai Wang, Y B Wang, Xiao Wang, Guobing Wang, Kangmei Wang, Chunguo Wang, Longcai Wang, Haina Wang, Chih-Hsien Wang, Yuli Wang, Ling-Ling Wang, Zhangshun Wang, Xue-Lian Wang, Jianxin Wang, Da-Yan Wang, Xianghua Wang, Peng Wang, Yu Qin Wang, Zhao-Jun Wang, Rui-Rui Wang, Xingyue Wang, Man Wang, Daozhong Wang, Tian-Li Wang, Luhui Wang, Gaopin Wang, Mengze Wang, Jizheng Wang, Hong-Yan Wang, Dongying Wang, Wenkai Wang, Stephani Wang, Dan-Dan Wang, Yicheng Wang, Yusheng Wang, Junwen Wang, Gao Wang, Ruo-Nan Wang, Yifan Wang, Jueqiong Wang, Xuewei Wang, Jianning Wang, Yonglun Wang, Shiwen Wang, Lifang Wang, Fuyan Wang, Jian-Bin Wang, Chonglong Wang, Haiwei Wang, Yike Wang, Chunxia Wang, Kaijuan Wang, Minglei Wang, Jingxiao Wang, Luting Wang, David Wang, Ben Wang, Ji-zheng Wang, Yuncong Wang, Lei P Wang, Tingye Wang, Wenke Wang, Ping Wang, Min Wang, Qiang-Sheng Wang, Xuejing Wang, Zhanju Wang, Xixi Wang, Xiaodong Wang, Chaomeng Wang, Yanong Wang, Xinghao Wang, Jiaming Wang, Siyuan Wang, Jiu Wang, Ruizhi Wang, Qing Mei Wang, Wenyi Wang, Yiqing Wang, Cai Ren Wang, Lianchun Wang, Xing-Ping Wang, Xiaoman Wang, Yanjin Wang, Xueqin Wang, Chenliang Wang, Zhenshan Wang, Junhong Wang, Guiping Wang, Xianrong Wang, Xumeng Wang, Dajia Wang, Huang Wang, Huie Wang, Weiwen Wang, Ruiwen Wang, Qing Wang, Haohao Wang, Bao-Long Wang, P Jeremy Wang, Chengqiang Wang, Suli Wang, Lingyan Wang, Chi Wang, Meng Wang, Luwen Wang, Quan Wang, Yan-Jun Wang, Sen Wang, Ruining Wang, Xiaozhen Wang, Zhiping Wang, Xue-Yao Wang, Yuming Wang, Jingjing Wang, Jiazheng Wang, Yunong Wang, Chongze Wang, Rufang Wang, Qiuning Wang, Tiannan Wang, Liqing Wang, Wencheng Wang, Xuefeng Wang, Yongli Wang, Xinwen Wang, Runzhi Wang, Chaojie Wang, Wentao Wang, Zhifeng Wang, Yanan Wang, Mengqi Wang, Limin Wang, Donglin Wang, Shujin Wang, Chengbin Wang, Qiu-Xia Wang, Zhengxuan Wang, Yancun Wang, Yuhuan Wang, Wei Wang, G-W Wang, Bangmao Wang, Kejia Wang, Jinjin Wang, Qifei Wang, Guobin Wang, Chun-Lin Wang, Jing-Shi Wang, Jiheng Wang, Huajing Wang, Yanlin Wang, Chuansheng Wang, Cailian Wang, Beilan Wang, Luofu Wang, Yangpeng Wang, Jieqi Wang, Weilin Wang, Xiaoxuan Wang, Yangyufan Wang, Xiao-Fei Wang, Chen-Ma Wang, Yun Yong Wang, Shizhi Wang, B Wang, Yuling Wang, Yi-Yi Wang, Fanwen Wang, Aiyun Wang, Jian Wang, Chengyu Wang, Jing-Huan Wang, Ning Wang, Yichuan Wang, L F Wang, Chau-Jong Wang, Xin-Yang Wang, Yunzhe Wang, Xuewen Wang, Sheng-Ping Wang, Bi Wang, Qiuting Wang, Yan-Jiang Wang, Dongshi Wang, Yingna Wang, Jingyue Wang, Hongshan Wang, Chunjiong Wang, Hong-Yang Wang, Yingmei Wang, Danfeng Wang, Zhongyi Wang, Teng Wang, Chih-Hao Wang, Mingchao Wang, Yi-Chuan Wang, Chuning Wang, Shihao Wang, Ming-Wei Wang, Menglu Wang, Zhulun Wang, Wuji Wang, Dao-Xin Wang, Han Wang, Jincheng Wang, Thomas T Y Wang, Qingyun Wang, Guoliang Wang, Jihong Wang, Hong-Qin Wang, G Wang, Hsei-Wei Wang, Linfang Wang, Xiao Ling Wang, Ganyu Wang, Zhengdong Wang, Cuizhe Wang, Hongyu Wang, Tieqiao Wang, Lijuan Wang, Jingchun Wang, Youzhao Wang, Zijian Wang, Ziheng Wang, Xingyu Wang, Shuning Wang, Shaokun Wang, Zhifu Wang, Xinqi Wang, Jinqiu Wang, ZhongXia Wang, Yanyun Wang, Dadong Wang, Xingjie Wang, Yiting Wang, Zhongli Wang, Junyu Wang, Jianding Wang, Meng-Wei Wang, Yingge Wang, Zhenchang Wang, Qun Wang, Jin-Xing Wang, Lijun Wang, Shuqing Wang, Fu-Yan Wang, Sheng-Nan Wang, Feijie Wang, Qiuyan Wang, Ying-Wei Wang, Shitao Wang, Meng-hong Wang, Zhengyang Wang, Jinghong Wang, Zhiying Wang, Pei Wang, Weixue Wang, Shiyue Wang, Xiaohong Wang, Daiwei Wang, Jinghua Wang, S X Wang, Jian-Yong Wang, Zeying Wang, Can Wang, Kehan Wang, Yunzhang Wang, Jinping Wang, Chenchen Wang, Chun-Ting Wang, Yujiao Wang, Xinxin Wang, Ji Wang, Sui Wang, Wenqiang Wang, Yingwei Wang, Shuzhen Wang, Daixi Wang, Yanming Wang, Lin-Yu Wang, Hongyin Wang, Zhongqun Wang, Er-Jin Wang, Yi Wang, Ziyi Wang, Lianghai Wang, Zhendan Wang, Xiao-Ming Wang, Chengyan Wang, Hui Miao Wang, Jingyi Wang, Ranran Wang, Banghui Wang, Huilun Wang, Ai-Ting Wang, Wenxuan Wang, Yuan-Hung Wang, Zixuan Wang, Hailing Wang, Xuan-Ying Wang, Jiqiu Wang, Yalong Wang, Xiaogang Wang, Shu-qiang Wang, Yun-Jin Wang, Zijie Wang, Tianlin Wang, Mingqiang Wang, Lufang Wang, Jin'e Wang, Xiru Wang, Cuili Wang, GuoYou Wang, Zhizhong Wang, Haifei Wang, Guorong Wang, Xinyue Wang, Pei-Juan Wang, Jiangong Wang, Yingte Wang, Huajin Wang, Ruibo Wang, Kejian Wang, Cheng-Cheng Wang, Xusheng Wang, Shu-Na Wang, Panliang Wang, Mingxi Wang, Shenqi Wang, Zifeng Wang, Chaozhan Wang, Xiuyuan Hugh Wang, Yuping Wang, Xujing Wang, Kai Wang, Hongbing Wang, Sheng-Yang Wang, Jianfei Wang, Hang Wang, Jing-Jing Wang, Weizhi Wang, Jixuan Wang, De-He Wang, P L Wang, Ningjian Wang, Chunyi Wang, Isabel Z Wang, Yong Wang, Yiming Wang, Mingzhi Wang, Jiying Wang, Qian-Wen Wang, Shusen Wang, Xiaoting Wang, Baogui Wang, Mingsong Wang, Zixia Wang, Demin Wang, Shiyuan Wang, Qiuli Wang, C Wang, Dongliang Wang, Weixiao Wang, Yinsheng Wang, Chunmei Wang, Huaili Wang, Xuelian Wang, Yongjun Wang, Zhi-Qin Wang, Jiaying Wang, Yulong Wang, Ren Wang, Jingnan Wang, Qishan Wang, Zeneng Wang, Guangsuo Wang, Chijia Wang, Huiqun Wang, Hongcai Wang, Donghao Wang, Xing-Jin Wang, Zongji Wang, Shenao Wang, Jiaqian Wang, Xiaoying Wang, Yilin Wang, Hangzhou Wang, Wenchao Wang, Jieyu Wang, Li-E Wang, Xuezhen Wang, Liuyang Wang, Zhiqian Wang, Fang-Tao Wang, Qiong Wang, Meng-Meng Wang, Youji Wang, Jiafeng Wang, Xiaojing Wang, William Wang, Junmin Wang, Laijian Wang, Xuexiang Wang, Huiyan Wang, T Y Wang, Zhaofu Wang, Wen-mei Wang, Yalin Wang, Xinshuai Wang, Daqi Wang, Zhen Wang, Shi-Cheng Wang, Anni Wang, Chunhong Wang, Hai-Long Wang, Pan Wang, Charles C N Wang, Pengxiang Wang, Xianzong Wang, Xike Wang, Qianliang Wang, Chunyan Wang, Xuan Wang, Xiaofen Wang, Zhi-Jian Wang, Feng-Sheng Wang, Xiangru Wang, R Wang, Yi-Shu Wang, Jia-Lin Wang, Yonghong Wang, Lintao Wang, Pai Wang, Yanfei Wang, Xuanwen Wang, Lei-Lei Wang, Chenxuan Wang, James Wang, Xinhui Wang, Shengqi Wang, Yueshen Wang, Shan-Shan Wang, Dingting Wang, Zhige Wang, Jingfeng Wang, Yongqing Wang, Chenyang Wang, Ziliang Wang, Bao Wang, Xueyan Wang, Liping Wang, Xingde Wang, Weijun Wang, Sibo Wang, Yaoling Wang, Donghong Wang, Chenyu Wang, Justin Wang, Baolong Wang, Yiqi Wang, Fengyong Wang, Lichao Wang, Yachen Wang, Quanren Wang, Shiyu Wang, Boyu Wang, Aimin Wang, Zhenghui Wang, Hengjiao Wang, Xiaoxin X Wang, Weimin Wang, Mutian Wang, Zhuo-Hui Wang, Xingye Wang, Zou Wang, Yu-Wen Wang, Shaoli Wang, Xin-Ming Wang, Weirong Wang, Kangli Wang, Yaoxing Wang, Xuejie Wang, Qifeng Wang, Xiaoxin Wang, Yinghui Wang, Jianzhang Wang, Tom J Wang, Yaqiong Wang, Zongwei Wang, Yun-Hui Wang, Haiyun Wang, Zhiyou Wang, Lijin Wang, Jifei Wang, Haiyong Wang, Xiao-Xia Wang, Shyi-Gang P Wang, Chih-Yang Wang, Zhixin Wang, Jun-Jun Wang, Tianjing Wang, Zhixia Wang, Chuanhai Wang, Zhijie Wang, Silu Wang, Jianguo Wang, Ming-Hsi Wang, Liling Wang, Yanting Wang, Haolong Wang, Xue-Lei Wang, Ru Wang, Qinglin Wang, Christina Wang, Mimi Wang, Menghui Wang, Wenju Wang, Junhua Wang, S S Wang, Fangyong Wang, Lifen Wang, Zhenbin Wang, Yapeng Wang, Shaoshen Wang, B R Wang, Sugai Wang, Hequn Wang, Songlin Wang, Wenjie Wang, Xiang-Dong Wang, Ting-Hua Wang, Mingliang Wang, Chengniu Wang, Guoxiang Wang, E Wang, Xiaochun Wang, Xueting Wang, Ming-Jie Wang, Zhaojing Wang, Dongxu Wang, Yirui Wang, Jiatao Wang, Jing-Min Wang, Shih-Wei Wang, Zhengchun Wang, Chaoxian Wang, Zehua Wang, Qiyu Wang, Shuye Wang, Baojun Wang, Qing Kenneth Wang, Xichun Wang, Jianliu Wang, Junping Wang, Yudong Wang, Mingzhu Wang, Kangning Wang, Wei-Ting Wang, Hongfang Wang, Chengwen Wang, Changduo Wang, Jinkang Wang, Junya Wang, Fengge Wang, Jianping Wang, Chang Wang, Zhifang Wang, Deli Wang, Linghua Wang, Shitian Wang, Lingling Wang, Zhihua Wang, Jun-Ling Wang, Keyi Wang, Lingbing Wang, Peijia Wang, Ruizhe Wang, X O Wang, Wanyi Wang, Ganggang Wang, Pei-Hua Wang, Kaiyue Wang, Xiaojiao Wang, Xun Wang, Shiyang Wang, Ya-Ping Wang, Yirong Wang, Lixing Wang, Danyang Wang, Xiaotang Wang, Taian Wang, Ming Wang, Xiangcheng Wang, Xuemei Wang, Zhixiong Wang, Mengying Wang, Li-Yong Wang, Xinchao Wang, Jianlong Wang, Jinjie Wang, Nan Wang, Weidong Wang, Mei-Gui Wang, L-S Wang, Wuqing Wang, Z Wang, Ya-Zhou Wang, Xincheng Wang, Jing-Wen Wang, Jinyue Wang, Hongyun Wang, Huaizhi Wang, Yan-Zi Wang, Danling Wang, Dongqin Wang, Hongzhuang Wang, Chung-Teng Wang, Yan-Chun Wang, Shi-Xin Wang, Muxuan Wang, Yujie Wang, Yunbing Wang, Yahui Wang, Zhihong Wang, Xiaoshan Wang, Tienju Wang, Chiou-Miin Wang, Yuqian Wang, Shengyuan Wang, Yumei Wang, Ningyuan Wang, Minjie Wang, Zhenda Wang, Qing-Dong Wang, Horng-Dar Wang, Siqi Wang, Kaihong Wang, Hong-Kai Wang, Meiling Wang, Jiaxing Wang, Xueyi Wang, Zhuozhong Wang, Anlai Wang, Julie Wang, Jin-Bao Wang, Keke Wang, Zhang Wang, Yintao Wang, Yong-Bo Wang, Bing Wang, Dalu Wang, Minxian Wang, Zulong Wang, Gao T Wang, Gang Wang, Sophie H Wang, Xinquan Wang, Yi-Ting Wang, Honglian Wang, Ruyue Wang, Jia-Qiang Wang, Seungwon Wang, Shusheng Wang, Yanbin Wang, Chang-Yun Wang, Le-Xin Wang, Juling Wang, Haohui Wang, Chuanyue Wang, Tianqin Wang, Danqing Wang, Keyan Wang, Yeou-Lih Wang, Qinglu Wang, Sun Wang, Rui-Min Wang, Yong-Tang Wang, Xianwei Wang, Lixia Wang, Tong Wang, Xiaonan Wang, Feida Wang, Jiaxuan Wang, Mingrui Wang, Zixiang Wang, Y Z Wang, Yuliang Wang, Ming-Chih Wang, J J Wang, Huina Wang, Jingang Wang, Jinyun Wang, Min-sheng Wang, Wanyao Wang, Ziqiu Wang, Guo-Quan Wang, Xueping Wang, Qixue Wang, Hechuan Wang, Shang Wang, Chaohan Wang, M H Wang, L Z Wang, Jianhui Wang, Xifeng Wang, Xiaorong Wang, Yinong Wang, Zhixiu Wang, Jiaxi Wang, Jiahui Wang, Xiaofei Wang, Feifei Wang, Kesheng Wang, Rong-Chun Wang, Zhi-Xin Wang, Chaoyu Wang, Yongkuan Wang, Zuoyan Wang, Hsueh-Chun Wang, Xixiang Wang, Guanrou Wang, Songsong Wang, Hongyuan Wang, Yubing Wang, Xuliang Wang, Wen-Ying Wang, Xinglei Wang, Dao-Wen Wang, Yun Wang, Ze Wang, Jiyan Wang, Zai Wang, Guan Wang, Chih-Chun Wang, Yiqin Wang, X S Wang, Hongzhan Wang, Exing Wang, Shu-Jin Wang, Shangyu Wang, Shouzhi Wang, Yunduan Wang, Jiyong Wang, Dongdong Wang, Qingzhong Wang, Zi-Qi Wang, Renyuan Wang, Siyu Wang, Donghui Wang, Ming-Yuan Wang, Juxiang Wang, Muxiao Wang, Fu Wang, Fei Wang, Qiuyu Wang, Ertao Wang, Zhi Xiao Wang, Zunxian Wang, Hui-Nan Wang, Rongping Wang, Won-Jing Wang, Leiming Wang, Pu Wang, Shen-Nien Wang, Xiaona Wang, Meng-Ying Wang, Wen-Jie Wang, Jiaxin Wang, RuNan Wang, Jiemei Wang, Ningli Wang, Zhong-Hui Wang, Hong Wang, Hui-Yu Wang, Ziqian Wang, Xinzhou Wang, Zhoufeng Wang, Weiguang Wang, Zusen Wang, Jiajia Wang, Bin Wang, Shu-Xia Wang, Yu'e Wang, Laidi Wang, Xiao-Li Wang, Lu Wang, Zhugang Wang, Maojie Wang, Ganglin Wang, Xinyu Wang, Junlin Wang, Dong Wang, Yao Wang, Ya-Jie Wang, Zhiwu Wang, DongWei Wang, Hongdan Wang, Yanxia Wang, Maiqiu Wang, Guansong Wang, Qingtong Wang, Yingcheng Wang, Wenjuan Wang, Xiaolong Wang, Weihao Wang, Qiushi Wang, Yingfei Wang, Haoyang Wang, Li-Li Wang, Yanbing Wang, Yingchun Wang, Guangming Wang, Kaiyuan Wang, Shiqi Wang, Qi-En Wang, Song Wang, Jing-Hao Wang, Lynn Yuning Wang, Zekun Wang, Rui-Ping Wang, Yining E Wang, Yuzhou Wang, Liu Wang, Maochun Wang, Cindy Wang, Qian-Liang Wang, Duo-Ping Wang, Linlin Wang, Taishu Wang, Xiang Wang, Qirui Wang, Baoming Wang, Liting Wang, Jiapan Wang, Lingda Wang, Xietong Wang, Jia-Mei Wang, Liwei Wang, Shaozheng Wang, Q Wang, Timothy C Wang, Mengyue Wang, Xing Wang, Yahong Wang, Yuyong Wang, Yujiong Wang, Guangliang Wang, Ya-Qin Wang, Yezhou Wang, Hongjian Wang, Su-Hua Wang, Qian-fei Wang, Meng-Dan Wang, Yuchen Wang, Hongpin Wang, Pengfei Wang, Ge Wang, Meijun Wang, Yan-Ming Wang, Haichao Wang, Tzung-Dau Wang, Runci Wang, Yan-Yi Wang, Cheng-Jie Wang, Chen-Yu Wang, Cong Wang, Yaxuan Wang, Y H Wang, Yongjie Wang, Yuntai Wang, Ranjing Wang, Yiru Wang, Anxiang Wang, Q Z Wang, Shimiao Wang, Guoping Wang, Junke Wang, Xingyun Wang, Zhengyi Wang, Shi-Qi Wang, Yanfeng Wang, Danxin Wang, Chaodong Wang, Zhiqi Wang, Chunyu Wang, Lijia Wang, Chunlong Wang, Haiping Wang, Qingfa Wang, Yu-Fan Wang, Baihan Wang, Chunxue Wang, Liewei Wang, Xinyi Wang, Fu-Zhen Wang, Qing-Mei Wang, Sheng Wang, Yi-Tao Wang, Dawei Wang, Xiaoyu Wang, Ziling Wang, Zhonglin Wang, Rurong Wang, Qingchun Wang, Qiang Wang, Suiyan Wang, Xu-Hong Wang, Jie Jin Wang, Chenyao Wang, Fei-Yan Wang, Shi Wang, Zhiyong Wang, Jieda Wang, Xiaoqi Wang, Linshu Wang, Ruxuan Wang, Qian Wang, Qianxu Wang, Fangjie Wang, Zhaoxia Wang, Jeremy R Wang, Mingmei Wang, Jingkang Wang, Jen-Chun Wang, Changyuan Wang, Chenglin Wang, Meng-Ru Wang, Tianpeng Wang, Zhongfang Wang, Xuedong Wang, Zhuoying Wang, Bingyu Wang, Xuelai Wang, Weilong Wang, Mengge Wang, Qin Wang, Da-Li Wang, Xuanyi Wang, Hongjuan Wang, Zhi-Hua Wang, Hong-Wei Wang, Yulai Wang, Gongming Wang, Yongni Wang, Mengya Wang, Yadong Wang, Chenghao Wang, Hongbo Wang, Kaiming Wang, Haonan Wang, Guanyun Wang, Yilu Wang, Quanxi Wang, Weiyuan Wang, Xiujun Wang, Liang-Yan Wang, Jianshe Wang, Yingxiong Wang, Cunchuan Wang, Jing-Zhai Wang, Yuelong Wang, Yuqi Wang, Xiaorui Wang, Qianjin Wang, Huijun Wang, Xiaobo Wang, Guoqian Wang, Luhong Wang, Kaining Wang, Chaohui Wang, Yanhong Wang, J-Y Wang, Qi-Bing Wang, Xiaohu Wang, Jiayan Wang, Cui-Shan Wang, Lulu Wang, Yong-Jie Wang, Shixuan Wang, Yuanyuan Wang, Jianying Wang, Haizhen Wang, Shuiliang Wang, Qianbao Wang, Jung-Pan Wang, Rixiang Wang, A Wang, Hanbing Wang, Caiqin Wang, Peigeng Wang, Yuan Wang, Yuzhuo Wang, Yubo Wang, Xianding Wang, Qiaoqi Wang, Cuiling Wang, Ai-Ling Wang, Hailong Wang, Yihao Wang, Lan-Wan Wang, Haihe Wang, S Wang, Sha Wang, Xiaoli Wang, David Q H Wang, Jianfang Wang, Yuting Wang, Jinhuan Wang, Kaixu Wang, Hongwei Wang, Yi-Wen Wang, Yizhe Wang, Shengyu Wang, Yanmei Wang, Huimin Wang, Youjie Wang, Kunhua Wang, Chongjian Wang, Ziyun Wang, Tianhui Wang, Huiying Wang, Yue-Nan Wang, Peiyin Wang, Hongbin Wang, Hong Yi Wang, Xinjun Wang, Yian Wang, Liyi Wang, Yunce Wang, Yi-Xuan Wang, Yitao Wang, Jiali Wang, Junqin Wang, Yuebing Wang, Yiping Wang, Yunpeng Wang, Yuxing Wang, Shuqi Wang, Ziyu Wang, Hongjie Wang, Xiaoyan Wang, Lianshui Wang, Xiaolu Wang, Wenya Wang, Fan Wang, Jinhua Wang, Sidan Wang, Lixiang Wang, Y L Wang, Xue-Rui Wang, Kai-Wen Wang, Zhongyu Wang, Xiaoyang Wang, Hongyang Wang, Rencheng Wang, Yinxiong Wang, Yuanli Wang, Zhuqing Wang, Y-H Wang, Yuhui Wang, Xitian Wang, Weizhen Wang, Qi Wang, Qiyuan Wang, Changlong Wang, Yatao Wang, Tengfei Wang, Yehan Wang
articles
Wenhua Zhang, Ruiming Wang, Fangying Shi · 2024 · Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association · Elsevier · added 2026-04-24
The purpose of this study is to the relationship between peripheral apolipoproteins and the prognosis of patients with acute ischemic stroke (AIS) after thrombolysis. A total of 231 AIS patients with Show more
The purpose of this study is to the relationship between peripheral apolipoproteins and the prognosis of patients with acute ischemic stroke (AIS) after thrombolysis. A total of 231 AIS patients with thrombolysis was enrolled. Serum apolipoproteins were measured on admission after thrombolysis. All patients enrolled were followed up for 90 days. Their functional outcomes were assessed by the modified Rankin Scale (mRS). Good functional outcome was considered as mRS < 3. Logistic regression was applied to assess the association between serum apolipoproteins and the mRS at 90 days. In multivariate analysis,1) ApoB (OR=0.099, 95%CI=0.017∼0.575, p=0.010) and ApoB/ApoA-1(OR=0.113, 95%CI=0.015∼0.868, p=0.036) were independent risk factors of good functional outcome at 90 days. 2). there were significant differences in the mRS score distribution at 90 days in groups according to the ROC cutoff values of ApoB (0.85g/L) and ApoB/ApoA-1 ratio (0.61) (all p<0.05). Our findings demonstrated ApoB and ApoB/apoA-1 ratio were independent risk factors for good functional outcome at 90 days, and the ApoB level below 0.85g/L and ApoB/ApoA-1 ratio below 0.61 could be associated with a better functional outcome in this study population. Show less
no PDF DOI: 10.1016/j.jstrokecerebrovasdis.2024.107944
APOB
Min Wang, Yanbin Liang, Yuce Qin +4 more · 2024 · Current pharmaceutical design · Bentham Science · added 2026-04-24
Diabetic cardiomyopathy (DCM) is a common diabetes complication with limited medications. Gegen Qinlian decoction (GQD) has been used in the treatment of diabetes and its related complications in Chin Show more
Diabetic cardiomyopathy (DCM) is a common diabetes complication with limited medications. Gegen Qinlian decoction (GQD) has been used in the treatment of diabetes and its related complications in China for several decades. In this study, network pharmacology was employed to predict the active ingredients, key targets, and pathways involved in the treatment of DCM by GQD and to validate it by animal experiments. The active ingredients of GQD were retrieved from TCMSP and published literature. DCM-related gene targets were searched in Drugbank, Genecards, Disgenet, and OMIM disease databases. Protein-protein interaction networks were constructed using the STRING database and Cytoscape. GO analysis and KEGG pathway enrichment analysis were performed using the Metascape platform. Moreover, a diabetic mouse model was established to evaluate the therapeutic effects of GQD by measuring serum biochemical markers and inflammation levels. Finally, the expression of predicted key target genes was determined using real-time quantitative PCR. A total of 129 active ingredients were screened from GQD. Moreover, 146 intersecting genes related to DCM were obtained, with key targets, including AKT1, TNF, IL6, and VEGFA. Lipid and atherosclerosis, AGE-RAGE, PI3K-AKT, and MAPK pathways were identified. Blood glucose control, decreased inflammatory factors, and serum CK-MB levels were restored after GQD intervention, and the same occurred with the expressions of PPAR-γ, AKT1, APOB, and GSK3B genes. Quercetin, kaempferol, wogonin, 7-methoxy-2-methyl isoflavone, and formononetin may exert major therapeutic effects by regulating key factors, such as AKT1, APOB, and GSK3B, in the inflammatory reaction, glycolipid oxidation, and glycogen synthesis related signaling pathways. Show less
no PDF DOI: 10.2174/0113816128312242240722080551
APOB
Yanhua Zhao, He Zhang, Shanshan Liang +2 more · 2024 · Clinica chimica acta; international journal of clinical chemistry · Elsevier · added 2026-04-24
Serum lipid profiles play a crucial role in diagnosing and evaluating cardiovascular diseases. However, the presence of paraprotein can lead to inaccurate dyslipidemia results on automated analyzers. Show more
Serum lipid profiles play a crucial role in diagnosing and evaluating cardiovascular diseases. However, the presence of paraprotein can lead to inaccurate dyslipidemia results on automated analyzers. A 65-year-old woman whose combined concentrations of HDL-cholesterol (HDL-C) and LDL-cholesterol (LDL-C) consistently surpassed her total serum cholesterol levels over a period of three months presented with unusual lipid component detection. Further analysis revealed the presence of a monoclonal paraprotein, identified as an IgMλ band, with a concentration of 28.0 g/L. The patient was subsequently diagnosed with Waldenström macroglobulinemia. The use of abnormal reaction kinetic curves and the β quantification method, along with an alternative method that did not suffer from interference, revealed that the monoclonal paraprotein interfered with the measurements of HDL-C, LDL-C, apolipoprotein A-I (apoA-I), and apolipoprotein B (apoB) when using the Roche detection system. This interference led to spurious elevated HDL-C concentrations and falsely decreased apoA-I and apoB concentrations, while the LDL-C results were minimally affected. Although diluting the sample normalized the HDL-C and LDL-C measurements, the interference with the apoA-I and apoB assays persisted. No other common biochemical tests were interfered with this paraprotein. Caution is advised when using a homogenous method for direct measurement of HDL-C and LDL-C in patients with monoclonal paraprotein. Techniques to recognize and eliminate this interference are available. However, immunoturbidimetric detection of apoA-I and apoB levels is also susceptible to this interference, which is not readily removable. Show less
no PDF DOI: 10.1016/j.cca.2024.119900
APOB
Yufeng Jin, Xin Wang, Ke Chen +10 more · 2024 · Lipids in health and disease · BioMed Central · added 2026-04-24
Despite centuries of traditional use of silymarin for hepatoprotection, current randomized controlled trial (RCT) studies on the effectiveness of silymarin in managing metabolic dysfunction-associated Show more
Despite centuries of traditional use of silymarin for hepatoprotection, current randomized controlled trial (RCT) studies on the effectiveness of silymarin in managing metabolic dysfunction-associated steatotic liver disease (MASLD) are limited and inconclusive, particularly when it is administered alone. The low bioavailability of silymarin highlights the possible influence of gut microbiota on the effectiveness of silymarin; however, no human studies have investigated this aspect. To determine the potential efficacy of silymarin in improving MASLD indicators and to investigate the underlying mechanisms related to gut microbiota. In this 24-week randomized, double-blind, placebo-controlled trial, 83 patients with MASLD were randomized to either placebo (n = 41) or silymarin (103.2 mg/d, n = 42). At 0, 12, and 24 weeks, liver stiffness and hepatic steatosis were assessed using FibroScan, and blood samples were gathered for biochemical detection, while faecal samples were collected at 0 and 24 weeks for 16S rRNA sequencing. Silymarin supplementation significantly reduced liver stiffness (LSM, -0.21 ± 0.17 vs. 0.41 ± 0.17, P = 0.015) and serum levels of γ-glutamyl transpeptidase (GGT, -8.21 ± 3.01 vs. 1.23 ± 3.16, P = 0.042) and ApoB (-0.02 ± 0.03 vs. 0.07 ± 0.03, P = 0.023) but had no significant effect on the controlled attenuation parameter (CAP), other biochemical indicators (aminotransferases, total bilirubin, glucose and lipid parameters, hsCRP, SOD, and UA), physical measurements (DBP, SBP, BMI, WHR, BF%, and BMR), or APRI and FIB-4 indices. Gut microbiota analysis revealed increased species diversity and enrichment of Oscillospiraceae in the silymarin group. These findings suggest that silymarin supplementation could improve liver stiffness in MASLD patients, possibly by modulating the gut microbiota. The trial was registered at the Chinese Clinical Trial Registry (ChiCTR2200059043). Show less
📄 PDF DOI: 10.1186/s12944-024-02220-y
APOB
Zhenqiu Liu, Huangbo Yuan, Yunzhi Wang +5 more · 2024 · Journal of proteome research · ACS Publications · added 2026-04-24
Liver oncogenesis is accompanied by discernible protein changes in the bloodstream. By employing plasma proteomic profiling, we can delve into the molecular mechanisms of liver cancer and pinpoint pot Show more
Liver oncogenesis is accompanied by discernible protein changes in the bloodstream. By employing plasma proteomic profiling, we can delve into the molecular mechanisms of liver cancer and pinpoint potential biomarkers. In this nested case-control study, we applied liquid chromatography-tandem mass spectrometry for proteome profiling in baseline plasma samples. Differential protein expression was determined and was subjected to functional enrichment, network, and Mendelian randomization (MR) analyses. We identified 193 proteins with notable differential levels between the groups. Of these proteins, MR analysis offered a compelling negative association between apolipoprotein B (APOB) and liver cancer. This association was further corroborated in the UK Biobank cohort: genetically predicted APOB levels were associated with a 31% (95% CI 19-42%) decreased risk of liver cancer; and phenotypic analysis indicated an 11% (95% CI 8-14%) decreased liver cancer risk for every 0.1 g/L increase of circulating APOB levels. Multivariable MR analysis suggested that the hepatic fat content might fully mediate the APOB-liver cancer connection. In summary, we identified some plasma proteins, particularly APOB, as potential biomarkers of liver cancer. Our findings underscore the intricate link between lipid metabolism and liver cancer, offering hints for targeted prophylactic strategies and early detection. Show less
no PDF DOI: 10.1021/acs.jproteome.4c00397
APOB
Danyang Zhao, Xiaoli Han, Qingshuang Mu +7 more · 2024 · Nutrition & metabolism · BioMed Central · added 2026-04-24
Apoprotein A-I (ApoA-I) and Apoprotein B (ApoB) have emerged as novel cardiovascular risk biomarkers influenced by feeding behavior. Hypothalamic appetite peptides regulate feeding behavior and impact Show more
Apoprotein A-I (ApoA-I) and Apoprotein B (ApoB) have emerged as novel cardiovascular risk biomarkers influenced by feeding behavior. Hypothalamic appetite peptides regulate feeding behavior and impact lipoprotein levels, which effects vary in different weight states. This study explores the intricate relationship between body mass index (BMI), hypothalamic appetite peptides, and apolipoproteins with emphasis on the moderating role of body weight in the association between neuropeptide Y (NPY), ghrelin, orexin A (OXA), oxytocin in cerebrospinal fluid (CSF) and peripheral ApoA-I and ApoB. In this cross-sectional study, we included participants with a mean age of 31.77 ± 10.25 years, categorized into a normal weight (NW) (n = 73) and an overweight/obese (OW/OB) (n = 117) group based on BMI. NPY, ghrelin, OXA, and oxytocin levels in CSF were measured. In the NW group, peripheral ApoA-I levels were higher, while ApoB levels were lower than in the OW/OB group (all p < 0.05). CSF NPY exhibited a positive correlation with peripheral ApoA-I in the NW group (r = 0.39, p = 0.001). Notably, participants with higher CSF NPY levels had higher peripheral ApoA-I levels in the NW group and lower peripheral ApoA-I levels in the OW/OB group, showing the significant moderating effect of BMI on this association (R This study provides hitherto undocumented evidence that BMI moderates the relationship between CSF NPY and peripheral ApoA-I levels. It also reveals the protective role of NPY in the NW population, contrasting with its risk factor role in the OW/OB population, which was associated with the at-risk for cardiovascular disease. Show less
📄 PDF DOI: 10.1186/s12986-024-00828-6
APOB
Li Sun, Jing-Xian Wang, Jing Ma +7 more · 2024 · Lipids in health and disease · BioMed Central · added 2026-04-24
Proprotein convertase subtilisins/kexin 6 (PCSK6) polymorphisms have been shown to be associated with atherosclerosis progression. This research aimed to evaluate the relationship of PCSK6 rs1531817 p Show more
Proprotein convertase subtilisins/kexin 6 (PCSK6) polymorphisms have been shown to be associated with atherosclerosis progression. This research aimed to evaluate the relationship of PCSK6 rs1531817 polymorphisms with coronary stenosis and the prognosis in premature myocardial infarction (PMI) patients. This prospective cohort analysis consecutively included 605 PMI patients who performed emergency percutaneous coronary intervention (PCI) at Tianjin Chest Hospital sequentially between January 2017 and August 2022, with major adverse cardiovascular events (MACEs) as the outcome. Analyses assessed the relationships among PCSK6 rs1531817 polymorphism, Gensini score (GS), triple vessel disease (TVD), and MACEs. 92 (16.8%) patients experienced MACEs with an average follow-up of 25.7 months. Logistic analysis revealed that the PCSK6 rs1531817 CA + AA genotype was an independent protective factor against high GS and TVD. Cox analysis revealed that the PCSK6 rs1531817 CA + AA genotype was an independent protective factor against MACEs. The mediation effect results showed that apolipoprotein A1/apolipoprotein B (ApoA1/ApoB) partially mediated the association between PCSK6 rs1531817 polymorphism and coronary stenosis and that total cholesterol/high-density lipoprotein (TC/HDL) and TVD partially and in parallel mediated the association between the PCSK6 rs1531817 polymorphism and MACEs. Patients with the PCSK6 CA + AA genotype have milder coronary stenosis and a better long-term prognosis; according to the mediation model, ApoA1/ApoB and TC/HDL partially mediate. These results may provide a new perspective on clinical therapeutic strategy for anti-atherosclerosis and improved prognosis in PMI patients. Show less
📄 PDF DOI: 10.1186/s12944-024-02206-w
APOB
Lisandro D Colantonio, Zhixin Wang, Jenna Jones +7 more · 2024 · JACC. Advances · Elsevier · added 2026-04-24
Low-density lipoprotein cholesterol (LDL-C) is used to guide lipid-lowering therapy after a myocardial infarction (MI). Lack of LDL-C testing represents a missed opportunity for optimizing therapy and Show more
Low-density lipoprotein cholesterol (LDL-C) is used to guide lipid-lowering therapy after a myocardial infarction (MI). Lack of LDL-C testing represents a missed opportunity for optimizing therapy and reducing cardiovascular risk. The purpose of this study was to estimate the proportion of Medicare beneficiaries who had their LDL-C measured within 90 days following MI hospital discharge. We conducted a retrospective cohort study of Medicare beneficiaries ≥66 years of age with an MI hospitalization between 2016 and 2020. The primary analysis used data from all beneficiaries with fee-for-service coverage and pharmacy benefits (532,767 MI hospitalizations). In secondary analyses, we used data from a 5% random sample of beneficiaries with fee-for-service coverage without pharmacy benefits (10,394 MI hospitalizations), and from beneficiaries with Medicare Advantage (176,268 MI hospitalizations). The proportion of beneficiaries who had their LDL-C measured following MI hospital discharge was estimated accounting for the competing risk of death. In the primary analysis (mean age 76.9 years, 84.4% non-Hispanic White), 29.9% of beneficiaries had their LDL-C measured within 90 days following MI hospital discharge. Among Hispanic, Asian, non-Hispanic White, and non-Hispanic Black beneficiaries, the 90-day postdischarge LDL-C testing was 33.8%, 32.5%, 30.0%, and 26.0%, respectively. Postdischarge LDL-C testing within 90 days was highest in the Middle Atlantic (36.4%) and lowest in the West North Central (23.4%) U.S. regions. In secondary analyses, the 90-day postdischarge LDL-C testing was 26.9% among beneficiaries with fee-for-service coverage without pharmacy benefits, and 28.6% among beneficiaries with Medicare Advantage coverage. LDL-C testing following MI hospital discharge among Medicare beneficiaries was low. Show less
📄 PDF DOI: 10.1016/j.jacadv.2023.100753
APOB
Su-Guo Wang, Yong-Gang Wang, Guo-Wei Qian +8 more · 2024 · Current medical science · Springer · added 2026-04-24
To investigate the serum lipid profiles of patients with localized osteosarcoma around the knee joint before and after neoadjuvant chemotherapy. After retrospectively screening the data of 742 patient Show more
To investigate the serum lipid profiles of patients with localized osteosarcoma around the knee joint before and after neoadjuvant chemotherapy. After retrospectively screening the data of 742 patients between January 2007 and July 2020, 50 patients aged 13 to 39 years with Enneking stage II disease were included in the study. Serum lipid levels, including total cholesterol (TC), triglycerides (TG), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), lipoprotein-α [Lp(a)], and apolipoprotein A1, B, and E (ApoA1, ApoB, and ApoE), and clinicopathological characteristics were collected before and after neoadjuvant chemotherapy. The mean levels of TC, TG, and ApoB were significantly increased following neoadjuvant chemotherapy (16%, 38%, and 20%, respectively, vs. pretreatment values; P<0.01). The mean levels of LDL-C and ApoE were also 19% and 16% higher, respectively (P<0.05). No correlation was found between the pretreatment lipid profile and the histologic response to chemotherapy. An increase in Lp(a) was strongly correlated with the Ki-67 index (R=0.31, P=0.023). Moreover, a trend toward longer disease-free survival (DFS) was observed in patients with decreased TG and increased LDL-C following chemotherapy, although this difference was not statistically significant (P=0.23 and P=0.24, respectively). Significant elevations in serum lipids were observed after neoadjuvant chemotherapy in patients with localized osteosarcoma. There was no prognostic significance of pretreatment serum lipid levels on histologic response to neoadjuvant chemotherapy. The scale of increase in serum Lp(a) might have a potential prognostic role in osteosarcoma. Patients with increased LDL-C or reduced TG after chemotherapy seem to exhibit a trend toward favorable DFS. Show less
📄 PDF DOI: 10.1007/s11596-024-2852-8
APOB
Hari K Krishnamurthy, Imbaasree Rajavelu, Swarnkumar Reddy +7 more · 2024 · Cureus · added 2026-04-24
Background  The study aims to assess the association of apolipoprotein E (APOE) gene polymorphisms with serological lipid and inflammatory markers to determine their potential role in predicting the r Show more
Background  The study aims to assess the association of apolipoprotein E (APOE) gene polymorphisms with serological lipid and inflammatory markers to determine their potential role in predicting the risk of cardiovascular diseases (CVDs) and Alzheimer's disease (AD).  Methodology  A total of 915 individuals underwent testing for lipid and inflammatory biomarkers at Vibrant America Clinical Laboratory. Clinical data, blood lipid and inflammatory profiles, and APOE genotyping were analyzed using polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP).  Results Compared to the E3/E3 genotype, individuals with E2/E3 genotypes showed higher levels of high-density lipoprotein (HDL), triglycerides, apolipoprotein A (APOA), high-sensitivity C-reactive protein (hs-CRP), and myeloperoxidase (MPO). E2/E4 genotype carriers had higher levels of HDL, triglycerides, Lp(a), and N-terminal pro b-type natriuretic peptide (BNPNT). E3/E4 genotypes were associated with elevated levels of total cholesterol, LDL, Lp(a), hs-CRP, small-density low-density lipoprotein (SDLDL), oxidized LDL (OXLDL), MPO, LDL-CAL, PLAC, and APOB. The E4/E4 group displayed higher concentrations of total cholesterol, LDL, APOB, Lp(a), hs-CRP, SDLDL, OXLDL, MPO, LDLCAL, and PLAC compared to E3/E3 carriers. These findings highlight the potential atherogenic effect of the ε4 allele and the protective effect of the ε2 allele based on lipid and inflammatory marker profiles.  Conclusions This study provides strong evidence linking APOE gene polymorphism to abnormal serum lipid and inflammatory profiles. Individuals carrying the ε4 alleles exhibited dysregulated lipid metabolism and abnormal inflammatory markers, increasing their risk of CVD and AD. Early detection and prompt diagnosis are crucial for implementing therapeutic, dietary, and lifestyle interventions to mitigate risks and prevent or delay lipid and inflammation-related disorders. Show less
📄 PDF DOI: 10.7759/cureus.60721
APOB
Shuqi Wang, Haina Gao, Mengmeng Zhang +1 more · 2024 · Diabetes, metabolic syndrome and obesity : targets and therapy · added 2026-04-24
To explore the relationship between vitamin D (VitD) deficiency and the apolipoprotein B/apolipoprotein A1 (apo B/A1) in type 2 diabetes mellitus (T2DM) patients. This was a retrospective study that l Show more
To explore the relationship between vitamin D (VitD) deficiency and the apolipoprotein B/apolipoprotein A1 (apo B/A1) in type 2 diabetes mellitus (T2DM) patients. This was a retrospective study that lasted 2 years and 6 months, collecting information and laboratory data from 784 patients with T2DM. Patients were divided into VitD deficiency group (n = 433) and non-VitD deficiency group (n = 351) based on VitD levels. Calculated apo B/A1 ratio, and patients were further divided into high-apo B/A1 group (n = 392) and low-apo B/A1 group (n = 392) based on the median of the apo B/A1. All data were analyzed using Prism 8.0.1 and R version 4.3.1 software. Apo B/A1 levels of T2DM patients combined with VitD deficiency was significantly higher than that of non-VitD deficiency patients, and the VitD levels of patients with high apo B/A1 was significantly lower than that patients with low apo B/A1 (all P<0.001). Spearman correlation analysis showed that VitD levels were negatively correlated with apo B/A1 (r=-0.238, P<0.001). Multiple linear regression analysis revealed after adjusting other factors, VitD levels were significantly negatively associated with apo B/A1 (β=-0.123, P=0.001). Binary logistic regression analysis showed apoB/A1 was an independent risk factor for VitD deficiency in T2DM patients. Restrictive cubic spline indicated a significant linear relationship between apoB/A1 and VitD deficiency (P general trend <0.0001, P nonlinear = 0.0896), after stratification of gender, the results showed that apo B/A1 was more susceptible to VitD deficiency in female patients. The receiver operating characteristic (ROC) curve analysis showed that the area under the curve, sensitivity and specificity of the apo B/A1 for VitD deficiency were 0.654, 66.3% and 59.8%, respectively. The apo B/A1 was significantly negatively associated with VitD levels and an independent risk factor for VitD deficiency in patients with T2DM. Show less
📄 PDF DOI: 10.2147/DMSO.S465391
APOB
Jiawen Lu, Yang Liu, Zhenqian Wang +4 more · 2024 · JACC. Asia · Elsevier · added 2026-04-24
Dyslipidemia is a recognized risk factor for type 2 diabetes (T2D), yet the genetic basis and causal nature remain unclear, particularly in Chinese populations. The authors investigated the causal eff Show more
Dyslipidemia is a recognized risk factor for type 2 diabetes (T2D), yet the genetic basis and causal nature remain unclear, particularly in Chinese populations. The authors investigated the causal effects of genetically predicted lipid levels on T2D risk and explored the potential effects of lipid-modifying drugs. Leveraging data from the Kunshan Community cohort in China, we analyzed the associations between low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol, and triglycerides (TGs) with T2D risk using genetic risk scores, 1-sample univariable, multivariable, and nonlinear Mendelian randomization (MR) analyses. Two-sample MR using summary-level data from Global Lipid Genetics Consortium and Biobank Japan was used for validation. Drug-target MR was used to examine the impact of lipid-modifying drug targets on T2D. Lower genetic risk scores of LDL-C (OR per SD: 0.97 [95% CI: 0.95-0.99]; Our findings suggested potential adverse effects of lower LDL-C, TG levels, as well as long-term use of APOC3 inhibitors on T2D risk in Chinese populations. These findings highlight the need for cautious lipid management strategies in T2D prevention. Show less
📄 PDF DOI: 10.1016/j.jacasi.2024.07.011
APOC3
Qianqian Xiao, Luyun Wang, Jing Wang +3 more · 2024 · Molecular metabolism · Elsevier · added 2026-04-24
Emerging evidence highlights the pivotal roles of long non-coding RNAs (lncRNAs) in lipid metabolism. Apoprotein C3 (ApoC3) is a well-established therapeutic target for hypertriglyceridemia and exhibi Show more
Emerging evidence highlights the pivotal roles of long non-coding RNAs (lncRNAs) in lipid metabolism. Apoprotein C3 (ApoC3) is a well-established therapeutic target for hypertriglyceridemia and exhibits a strong association with cardiovascular disease. However, the exact mechanisms via which the lncRNAs control ApoC3 expression remain unclear. We identified a novel long noncoding RNA (lncRNA), GM47544, within the ApoA1/C3/A4/A5 gene cluster. Subsequently, the effect of GM47544 on intracellular triglyceride metabolism was analyzed. The diet-induced mouse models of hyperlipidemia and atherosclerosis were established to explore the effect of GM47544 on dyslipidemia and plaque formation in vivo. The molecular mechanism was explored through RNA sequencing, immunoprecipitation, RNA pull-down assay, and RNA immunoprecipitation. GM47544 was overexpressed under high-fat stimulation. GM47544 effectively improved hepatic steatosis, reduced blood lipid levels, and alleviated atherosclerosis in vitro and in vivo. Mechanistically, GM47544 directly bound to ApoC3 and facilitated the ubiquitination at lysine 79 in ApoC3, thereby facilitating ApoC3 degradation via the ubiquitin-proteasome pathway. Moreover, we identified AP006216.5 as the human GM47544 transcript, which fulfills a comparable function in human hepatocytes. The identification of GM47544 as a lncRNA modulator of ApoC3 reveals a novel mechanism of post-translational modification, with significant clinical implications for the treatment of hypertriglyceridemia and atherosclerosis. Show less
📄 PDF DOI: 10.1016/j.molmet.2024.102011
APOC3
Lixuan Huang, Ying Sun, Chao Luo +5 more · 2024 · Frontiers in pharmacology · Frontiers · added 2026-04-24
Schizophrenia significantly impacts cognitive and behavioral functions and is primarily treated with second-generation antipsychotics (SGAs) such as olanzapine. Despite their efficacy, these drugs are Show more
Schizophrenia significantly impacts cognitive and behavioral functions and is primarily treated with second-generation antipsychotics (SGAs) such as olanzapine. Despite their efficacy, these drugs are linked to serious metabolic side effects which can diminish patient compliance, worsen psychiatric symptoms and increase cardiovascular disease risk. This study explores the hypothesis that SGAs affect the molecular determinants of synaptic plasticity and brain activity, particularly focusing on the lateral septum (LS) and its interactions within hypothalamic circuits that regulate feeding and energy expenditure. Utilizing functional ultrasound imaging, RNA sequencing, and weighted gene co-expression network analysis, we identified significant alterations in the functional connection between the hypothalamus and LS, along with changes in gene expression in the LS of mice following prolonged olanzapine exposure. Our analysis revealed a module closely linked to increases in body weight and adiposity, featuring genes primarily involved in lipid metabolism pathways, notably Show less
📄 PDF DOI: 10.3389/fphar.2024.1419098
APOC3
Jiacheng Lyu, Lin BAI, Yumiao Li +12 more · 2024 · Nature communications · Nature · added 2026-04-24
Dual blocker therapy (DBT) has the enhanced antitumor benefits than the monotherapy. Yet, few effective biomarkers are developed to monitor the therapy response. Herein, we investigate the DBT longitu Show more
Dual blocker therapy (DBT) has the enhanced antitumor benefits than the monotherapy. Yet, few effective biomarkers are developed to monitor the therapy response. Herein, we investigate the DBT longitudinal plasma proteome profiling including 113 longitudinal samples from 22 patients who received anti-PD1 and anti-CTLA4 DBT therapy. The results show the immune response and cholesterol metabolism are upregulated after the first DBT cycle. Notably, the cholesterol metabolism is activated in the disease non-progressive group (DNP) during the therapy. Correspondingly, the clinical indicator prealbumin (PA), free triiodothyronine (FT3) and triiodothyronine (T3) show significantly positive association with the cholesterol metabolism. Furthermore, by integrating proteome and radiology approach, we observe the high-density lipoprotein partial remodeling are activated in DNP group and identify a candidate biomarker APOC3 that can reflect DBT response. Above, we establish a machine learning model to predict the DBT response and the model performance is validated by an independent cohort with balanced accuracy is 0.96. Thus, the plasma proteome profiling strategy evaluates the alteration of cholesterol metabolism and identifies a panel of biomarkers in DBT. Show less
📄 PDF DOI: 10.1038/s41467-024-47835-y
APOC3
Runhao Xu, Jianan Shen, Yan Song +5 more · 2024 · Scientific reports · Nature · added 2026-04-24
Analyzing blood lipid and bile acid profile changes in colorectal cancer (CRC) patients. Evaluating the integrated model's diagnostic significance for CRC. Ninety-one individuals with colorectal cance Show more
Analyzing blood lipid and bile acid profile changes in colorectal cancer (CRC) patients. Evaluating the integrated model's diagnostic significance for CRC. Ninety-one individuals with colorectal cancer (CRC group) and 120 healthy volunteers (HC group) were selected for comparison. Serum levels of total cholesterol (TC), triglycerides (TG), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), and apolipoproteins (Apo) A1, ApoA2, ApoB, ApoC2, and ApoC3 were measured using immunoturbidimetric and colorimetric methods. Additionally, LC-MS/MS was employed to detect fifteen bile acids in the serum, along with six tumor markers: carcinoembryonic antigen (CEA), carbohydrate antigens (CA) 125, CA19-9, CA242, CA50, and CA72-4. Group comparisons utilized independent sample t-tests and Mann-Whitney U tests. A binary logistic regression algorithm was applied to fit the indicators and establish a screening model; the diagnostic accuracy of individual Indicators and the model was analyzed using receiver operating characteristic (ROC) curves. The CRC group showed significantly lower levels in eight serum lipid indicators and eleven bile acids compared to the HC group (P < 0.05). Conversely, serum levels of TG, CA19-9, and CEA were elevated (P < 0.05). Among the measured parameters, ApoA2 stands out for its strong correlation with the presence of CRC, showcasing exceptional screening efficacy with an area under the curve (AUC) of 0.957, a sensitivity of 85.71%, and a specificity of 93.33%. The screening model, integrating ApoA1, ApoA2, lithocholic acid (LCA), and CEA, attained an impressive AUC of 0.995, surpassing the diagnostic accuracy of individual lipids, bile acids, and tumor markers. CRC patients manifest noteworthy alterations in both blood lipids and bile acid profiles. A screening model incorporating ApoA1, ApoA2, LCA, and CEA provides valuable insights for detecting CRC. Show less
📄 PDF DOI: 10.1038/s41598-024-60867-0
APOC3
Shaoliang Zhu, Quan Cheng, Mengjie Zou +11 more · 2024 · Journal of cellular and molecular medicine · Blackwell Publishing · added 2026-04-24
Pancreatic ductal adenocarcinoma (PDAC), a very aggressive tumour, is currently the third leading cause of cancer-related deaths. Unfortunately, many patients face the issue of inoperability at the di Show more
Pancreatic ductal adenocarcinoma (PDAC), a very aggressive tumour, is currently the third leading cause of cancer-related deaths. Unfortunately, many patients face the issue of inoperability at the diagnostic phase leading to a quite dismal prognosis. The onset of metastatic processes has a crucial role in the elevated mortality rates linked to PDAC. Individuals with metastatic advances receive only palliative therapy and have a grim prognosis. It is essential to carefully analyse the intricacies of the metastatic process to enhance the prognosis for individuals with PDAC. Malignancy development is greatly impacted by the process of macrophage efferocytosis. Our current knowledge about the complete range of macrophage efferocytosis activities in PDAC and their intricate interactions with tumour cells is still restricted. This work aims to resolve communication gaps and pinpoint the essential transcription factor that is vital in the immunological response of macrophage populations. We analysed eight PDAC tissue samples sourced from the gene expression omnibus. We utilized several software packages such as Seurat, DoubletFinder, Harmony, Pi, GSVA, CellChat and Monocle from R software together with pySCENIC from Python, to analyse the single-cell RNA sequencing (scRNA-seq) data collected from the PDAC samples. This study involved the analysis of a comprehensive sample of 22,124 cells, which were classified into distinct cell types. These cell types encompassed endothelial and epithelial cells, PDAC cells, as well as various immune cells, including CD4+ T cells, CD8+ T cells, NK cells, B cells, plasma cells, mast cells, monocytes, DC cells and different subtypes of macrophages, namely C0 macrophage TGM2+, C1 macrophage PFN1+, C2 macrophage GAS6+ and C3 macrophage APOC3+. The differentiation between tumour cells and epithelial cells was achieved by the implementation of CopyKat analysis, resulting in the detection and categorization of 1941 PDAC cells. The amplification/deletion patterns observed in PDAC cells on many chromosomes differ significantly from those observed in epithelial cells. The study of Pseudotime Trajectories demonstrated that the C0 macrophage subtype expressing TGM2+ had the lowest level of differentiation. Additionally, the examination of gene set scores related to efferocytosis suggested that this subtype displayed higher activity during the efferocytosis process compared to other subtypes. The most active transcription factors for each macrophage subtype were identified as BACH1, NFE2, TEAD4 and ARID3A. In conclusion, the examination of human PDAC tissue samples using immunofluorescence analysis demonstrated the co-localization of CD68 and CD11b within regions exhibiting the presence of keratin (KRT) and alpha-smooth muscle actin (α-SMA). This observation implies a spatial association between macrophages, fibroblasts, and epithelial cells. There is variation in the expression of efferocytosis-associated genes between C0 macrophage TGM2+ and other macrophage cell types. This observation implies that the diversity of macrophage cells might potentially influence the metastatic advancement of PDAC. Moreover, the central transcription factor of different macrophage subtypes offers a promising opportunity for targeted immunotherapy in the treatment of PDAC. Show less
📄 PDF DOI: 10.1111/jcmm.18266
APOC3
Mei-Jie Chen, Yi-Tong Xu, Lu Sun +6 more · 2024 · Acta pharmacologica Sinica · Nature · added 2026-04-24
Within the context of residual cardiovascular risk in post-statin era, emerging evidence from epidemiologic and human genetic studies have demonstrated that triglyceride (TG)-rich lipoproteins and the Show more
Within the context of residual cardiovascular risk in post-statin era, emerging evidence from epidemiologic and human genetic studies have demonstrated that triglyceride (TG)-rich lipoproteins and their remnants are causally related to cardiovascular risk. While, carriers of loss-of-function mutations of ApoC3 have low TG levels and are protected from cardiovascular disease (CVD). Of translational significance, siRNAs/antisense oligonucleotide (ASO) targeting ApoC3 is beneficial for patients with atherosclerotic CVD. Therefore, animal models of atherosclerosis with both hypercholesterolemia and hypertriglyceridemia are important for the discovery of novel therapeutic strategies targeting TG-lowering on top of traditional cholesterol-lowering. In this study, we constructed a novel mouse model of familial combined hyperlipidemia through inserting a human ApoC3 transgene (hApoC3-Tg) into C57BL/6 J mice and injecting a gain-of-function variant of adeno-associated virus-proprotein convertase subtilisin/kexin type 9 (AAV-PCSK9)-D377Y concurrently with high cholesterol diet (HCD) feeding for 16 weeks. In the last 10 weeks, hApoC3-Tg mice were orally treated with a combination of atorvastatin (10 mg·kg Show less
no PDF DOI: 10.1038/s41401-024-01241-8
APOC3
Quanxin Su, Rui Wang, Yayin Luo +2 more · 2024 · Frontiers in endocrinology · Frontiers · added 2026-04-24
The effect of hypolipidemic drugs on male erectile function is still controversial. This Mendelian randomization (MR) study aimed to explore the potential impact of lipid-lowering drug targets on ED. Show more
The effect of hypolipidemic drugs on male erectile function is still controversial. This Mendelian randomization (MR) study aimed to explore the potential impact of lipid-lowering drug targets on ED. We collected seven genetic variants encoding lipid-lowering drug targets (LDLR, HMGCR, NPC1L1, PCSK9, APOB, APOC3 and LPL) from published genome-wide association study (GWAS) statistics, and performed drug target MR analysis. The risk of ED was defined as the primary outcome, sex hormone levels and other diseases as the secondary outcomes. Mediation analyses were performed to explore potential mediating factors. The results showed that LDLR, LPL agonists and APOC3 inhibitors were significantly associated with a reduced risk of ED occurrence. APOB inhibitors were associated with an increased risk of ED occurrence. In terms of sex hormone levels, LDLR and LPL agonists were significantly associated with increased TT levels, and HMGCR was associated with decreased TT and BT levels significantly. In terms of male-related disease, MR results showed that LDLR agonists and PCSK9 inhibitors were significantly associated with an elevated risk of PH; HMGCR, NPC1L1 inhibitors were associated with a reduced risk of PCa; and LDLR agonists were significantly associated with a reduced risk of AS and MI; in addition, HMGCR inhibitors were associated with a reduced risk of PCa. After performing drug-targeted MR analysis, we found that that there was a causal relationship between lipid-lowering drug targets and ED. APOC3, APOB, LDLR and LPL may be new candidate drug targets for the treatment of ED. Show less
📄 PDF DOI: 10.3389/fendo.2024.1362499
APOC3
Zhichen Pu, Wenhui Wang, Haitang Xie +1 more · 2024 · International immunopharmacology · Elsevier · added 2026-04-24
Respiratory failure caused by severe acute lung injury (ALI) is the main cause of mortality in patients with COVID-19.This study aimed to investigate the effects and underlying biological mechanism of Show more
Respiratory failure caused by severe acute lung injury (ALI) is the main cause of mortality in patients with COVID-19.This study aimed to investigate the effects and underlying biological mechanism of Apolipoprotein C3 (ApoC3) in ALI. To establish an in vivo model, C57BL/6 mice were exposed by lipopolysaccharide (LPS). For the in vitro model, murine bone marrow-derived macrophages (BMDMs) or RAW264.7 cells were stimulated with LPS + adenosine triphosphate (ATP). Serum levels of ApoC3 were found to be upregulated in patients with COVID-19 or pneumonia-induced ALI. Inhibition of ApoC3 reduced lung injury in an ALI model, while overexpression of ApoC3 promoted lung injury. ApoC3 induced mitochondrial damage-mediated pyroptosis in ALI through the activation of the NOD-like receptorprotein 3 (NLRP3) inflammasome. ApoC3 recombinant protein significantly increased SCIMP expression in the lung tissue of mice models with ALI. ApoC3 also facilitated the interaction between the SLP adapter and CSK-interacting membrane protein (SCIMP) protein and Spleen tyrosine kinase (SYK) protein in the ALI model. Moreover, ApoC3 accelerated calcium-dependent reactive oxygen species (ROS) production in the ALI model. The effects of ApoC3 on pyroptosis were mitigated by the use of a pyroptosis inhibitor or an ROS inhibitor in the ALI model. Furthermore, ApoC3 activated the expression of SYK, which in turn induced NLRP3 inflammasome-regulated pyroptosis in the ALI model. METTL3 was found to mediate the m6A mRNA expression of ApoC3. Overall, our study highlights the crucial role of ApoC3 in promoting macrophage pyroptosis in ALI through calcium-dependent ROS production and NLRP3 inflammasome activation via the SCIMP-SYK pathway, providing a potential therapeutic strategy for ALI and other inflammatory diseases. Show less
no PDF DOI: 10.1016/j.intimp.2024.111537
APOC3
Jiawei Liao, Yuhui Wang, Yao Wang +5 more · 2024 · Biochimica et biophysica acta. Molecular and cell biology of lipids · Elsevier · added 2026-04-24
no PDF DOI: 10.1016/j.bbalip.2023.159449
APOC3
Xue Zhang, Longtao Ji, Man Liu +11 more · 2024 · Journal of proteome research · ACS Publications · added 2026-04-24
Given the pressing clinical problem of making a decision in diagnosis for subjects with pulmonary nodules, we aimed to discover novel plasma protein biomarkers for lung adenocarcinoma (LUAD) and benig Show more
Given the pressing clinical problem of making a decision in diagnosis for subjects with pulmonary nodules, we aimed to discover novel plasma protein biomarkers for lung adenocarcinoma (LUAD) and benign pulmonary nodules (BPNs) and then develop an integrative multianalytical model to guide the clinical management of LUAD and BPN patients. Through label-free quantitative plasma proteomic analysis (data are available via ProteomeXchange with identifier PXD046731), 12 differentially expressed proteins (DEPs) in LUAD and BPN were screened. The diagnostic abilities of DEPs were validated in two independent validation cohorts. The results showed that the levels of three candidate proteins (PRDX2, PON1, and APOC3) were lower in the plasma of LUAD than in BPN. The three candidate proteins were combined with three promising computed tomography indicators (spiculation, vascular notch sign, and lobulation) and three traditional markers (CEA, CA125, and CYFRA21-1) to construct an integrative multianalytical model, which was effective in distinguishing LUAD from BPN, with an AUC of 0.904, a sensitivity of 81.44%, and a specificity of 90.14%. Moreover, the model possessed impressive diagnostic performance between early LUADs and BPNs, with the AUC, sensitivity, specificity, and accuracy of 0.868, 65.63%, 90.14%, and 82.52%, respectively. This model may be a useful auxiliary diagnostic tool for LUAD and BPN by achieving a better balance of sensitivity and specificity. Show less
no PDF DOI: 10.1021/acs.jproteome.3c00551
APOC3
Brandon M Lehrich, Evan R Delgado, Tyler M Yasaka +31 more · 2024 · Research square · added 2026-04-24
First-line immune checkpoint inhibitor (ICI) combinations show responses in subsets of hepatocellular carcinoma (HCC) patients. Nearly half of HCCs are Wnt-active with mutations in
📄 PDF DOI: 10.21203/rs.3.rs-5494074/v1
AXIN1
Jianding Wang, Wenwen Zhang, Rui Zhang +4 more · 2024 · Toxics · MDPI · added 2026-04-24
N-methyl-n'-nitroso-n'-nitroso guanidine (MNNG) can induce esophageal squamous cell carcinoma (ESCC), and microRNAs are associated with the development of ESCC and may serve as potential tumor prognos Show more
N-methyl-n'-nitroso-n'-nitroso guanidine (MNNG) can induce esophageal squamous cell carcinoma (ESCC), and microRNAs are associated with the development of ESCC and may serve as potential tumor prognostic markers. Thus, the aim of this study was to evaluate the potential function of miR-101-3p in MNNG-induced ESCC. An investigation of risk factors in patients with ESCC was carried out and the concentration of nine nitrosamines in urine samples was detected by the SPE-GC-MS technique. Then, we performed cancer tissue gene sequencing analysis, and RT-qPCR verified the expression level of miR-101-3p. Subsequently, the relationship between miR-101-3p potential target genes and the ESCC patients' prognosis was predicted. Finally, we investigated the function of miR-101-3p in MNNG-induced ESCC pathogenesis and the regulatory mechanism of the signaling pathway by in vivo and in vitro experiments. The results revealed that high dietary nitrosamine levels are high-risk factors for ESCC. MiR-101-3p is down-regulated in ESCC tissues and cells, and its potential target genes are enriched in cell migration and cancer-related pathways. MiR-101-3p target genes include AXIN1, CK1, and GSK3, which are involved in the regulation of the Wnt signaling pathway. MiR-101-3p overexpression promotes apoptosis and inhibits the proliferation and migration of Eca109 cells. The Wnt pathway is activated after subchronic exposure to MNNG, and the Wnt pathway is inhibited by the overexpression of miR-101-3p in Eca109 cells. Down-regulated miR-101-3p may exert tumor suppressive effects by regulating the Wnt pathway and may be a useful biomarker for predicting ESCC progression. Show less
📄 PDF DOI: 10.3390/toxics12110824
AXIN1
Zehua Wen, Lei Wang, Shi-Wei Liu +3 more · 2024 · Cells · MDPI · added 2026-04-24
Wnt signaling is involved in embryo development and cancer. The binding between the DIX domains of Axin1/2, Dishevelled1/2/3, and Coiled-coil-DIX1 is essential for Wnt/β-catenin signaling. Structural Show more
Wnt signaling is involved in embryo development and cancer. The binding between the DIX domains of Axin1/2, Dishevelled1/2/3, and Coiled-coil-DIX1 is essential for Wnt/β-catenin signaling. Structural and biological studies have revealed that DIX domains are polymerized through head-to-tail interface interactions, which are indispensable for activating β-catenin Wnt signaling. Although different isoforms of Dvl and Axin proteins display both redundant and specific functions in Wnt signaling, the specificity of DIX-mediated interactions remains unclear due to technical challenges. Using AlphaFold2(AF2), we predict the structures of 6 homodimers and 22 heterodimers of DIX domains without templates and compare them with the reported X-ray complex structures. PRODIGY is used to calculate the binding affinities of these DIX complexes. Our results show that the Axin2 DIX homodimer has a stronger binding affinity than the Axin1 DIX homodimer. Among Dishevelled (Dvl) proteins, the binding affinity of the Dvl1 DIX homodimer is stronger than that of Dvl2 and Dvl3. The Coiled-coil-DIX1(Ccd1) DIX homodimer shows weaker binding than the Axin1 DIX homodimer. Generally, heterodimer interactions tend to be stronger than those of homodimers. Our findings provide insights into the mechanism of the Wnt signaling pathway and highlight the potential of AF2 and PRODIGY for studying protein-protein interactions in signaling pathways. Show less
📄 PDF DOI: 10.3390/cells13191646
AXIN1
Zhiguo Wang, Kunlin Li, Conghua Lu +12 more · 2024 · Oncology research · added 2026-04-24
Metformin has pleiotropic effects beyond glucose reduction, including tumor inhibition and immune regulation. It enhanced the anti-tumor effects of programmed cell death protein 1 (PD-1) inhibitors in Show more
Metformin has pleiotropic effects beyond glucose reduction, including tumor inhibition and immune regulation. It enhanced the anti-tumor effects of programmed cell death protein 1 (PD-1) inhibitors in serine/threonine kinase 11 ( We performed untargeted metabolomics using liquid chromatography (LC)-mass spectrometry (MS)/MS system and conducted cell experiments to verify the results of bioinformatics analysis. According to the Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway database, most metabolites were annotated into metabolism, including nucleotide metabolism. Next, the differentially expressed metabolites in H460 (refers to H460 cells), H460_met (refers to metformin-treated H460 cells), and H460_KO_met (refers to metformin-treated Relying on AXIN1, metformin upregulated multiple nucleotide metabolites which promoted STING signaling and the killing of activated T cells in Show less
📄 PDF DOI: 10.32604/or.2024.052664
AXIN1
Tiantian Wu, Hui Zhou, Lulu Wang +8 more · 2024 · Heliyon · Elsevier · added 2026-04-24
Tripartite motif-containing protein 59 (TRIM59) is a biomarker for multiple tumors with crucial roles. However, the specific role of TRIM59 in germ cells remains largely unknown. Here, we investigated Show more
Tripartite motif-containing protein 59 (TRIM59) is a biomarker for multiple tumors with crucial roles. However, the specific role of TRIM59 in germ cells remains largely unknown. Here, we investigated the effects and underlying regulatory mechanisms of TRIM59 on germ cells using the mouse spermatogonial cell line GC-1. Our results demonstrated that TRIM59 promoted proliferation and inhibited apoptosis of GC-1 cells. Mechanistically, TRIM59 maintained GC-1 cell behaviors through ubiquitination of AXIN1 to activate β-catenin signaling. Furthermore, activation of β-catenin signaling reversed the effects mediated by Show less
📄 PDF DOI: 10.1016/j.heliyon.2024.e36744
AXIN1
Shengxi Shen, Ping Wang, Pei Wu +4 more · 2024 · Molecular therapy : the journal of the American Society of Gene Therapy · Elsevier · added 2026-04-24
Wnt/β-catenin signaling is an attractive target for regenerative medicine. A powerful driver of stem cell activity and hence tissue regeneration, Wnt signaling can promote fibroblast proliferation and Show more
Wnt/β-catenin signaling is an attractive target for regenerative medicine. A powerful driver of stem cell activity and hence tissue regeneration, Wnt signaling can promote fibroblast proliferation and activation, leading to fibrosis, while prolonged Wnt signaling is potentially carcinogenic. Thus, to harness its therapeutic potential, the activation of Wnt signaling must be transient, reversible, and tissue specific. In the lung, Wnt signaling is essential for alveolar stem cell activity and alveolar regeneration, which is impaired in lung fibrosis. Activation of Wnt/β-catenin signaling in lung epithelium may have anti-fibrotic effects. Here, we used intratracheal adeno-associated virus 6 injection to selectively deliver CasRx into the lung epithelium, where it reversibly activates Wnt signaling by simultaneously degrading mRNAs encoding Axin1 and Axin2, negative regulators of Wnt/β-catenin signaling. Interestingly, CasRx-mediated Wnt activation specifically in lung epithelium not only promotes alveolar type II cell proliferation and alveolar regeneration but also inhibits lung fibrosis resulted from bleomycin-induced injury, relevant in both preventive and therapeutic settings. Our study offers an attractive strategy for treating pulmonary fibrosis, with general implications for regenerative medicine. Show less
📄 PDF DOI: 10.1016/j.ymthe.2024.09.008
AXIN1
Fangchen Gong, Wenbin Liu, Lei Pei +10 more · 2024 · Frontiers in endocrinology · Frontiers · added 2026-04-24
Sepsis, a life-threatening condition, involves complex interactions among metabolic alterations, inflammatory mediators, and host responses. This study utilized a bidirectional Mendelian randomization Show more
Sepsis, a life-threatening condition, involves complex interactions among metabolic alterations, inflammatory mediators, and host responses. This study utilized a bidirectional Mendelian randomization approach to investigate the causal relationships between 1400 metabolites and sepsis, and the mediating role of inflammatory factors. We identified 36 metabolites significantly associated with sepsis (p < 0.05), with AXIN1, FGF-19, FGF-23, IL-4, and OSM showing an inverse association, suggesting a protective role, while IL-2 exhibited a positive correlation, indicating a potential risk factor. Among these metabolites, Piperine and 9-Hydroxystearate demonstrated particularly interesting protective effects against sepsis. Piperine's protective effect was mediated through its interaction with AXIN1, contributing to a 16.296% reduction in sepsis risk. This suggests a potential pathway where Piperine influences sepsis outcomes by modulating AXIN1 levels. 9-Hydroxystearate also exhibited a protective role against sepsis, mediated through its positive association with FGF-19 and negative association with IL-2, contributing 9.436% and 12.565%, respectively, to its protective effect. Experimental validation confirmed significantly elevated IL-2 levels and reduced FGF-19, AXIN1, piperine, and 9-hydroxyoctadecanoic acid levels in sepsis patients compared to healthy controls. Piperine levels positively correlated with AXIN1, while 9-hydroxyoctadecanoic acid levels negatively correlated with IL-2 and positively correlated with FGF-19, supporting the Mendelian randomization findings. Our findings provide insights into the molecular mechanisms of sepsis, highlighting the unique roles and contributions of specific metabolites and their interactions with inflammatory mediators. This study enhances our understanding of sepsis pathophysiology and opens avenues for targeted therapeutic interventions and biomarker development for sepsis management. However, further research is essential to validate these pathways across diverse populations and fully explore the roles of these metabolites in sepsis. Show less
📄 PDF DOI: 10.3389/fendo.2024.1377755
AXIN1
H Li, G Li, X Zhang +1 more · 2024 · Nan fang yi ke da xue xue bao = Journal of Southern Medical University · added 2026-04-24
H Li, G Li, X Zhang, Y Wang Show less
To explore the causal relationship between inflammatory protein markers and the risk of colorectal cancer using a Mendelian randomization (MR) approach. We obtained data pertaining to colorectal cance Show more
To explore the causal relationship between inflammatory protein markers and the risk of colorectal cancer using a Mendelian randomization (MR) approach. We obtained data pertaining to colorectal cancer from Genome-Wide Association Study (GWAS) datasets and used 91 inflammatory protein markers as the exposure variables. A two-sample MR analysis model was used to assess the causal link between the inflammatory markers and colorectal cancer risk. The robustness of the results was evaluated through heterogeneity, pleiotropy, and sensitivity analyses using 5 MR models: Inverse Variance Weighted (IVW), Weighted Median, MR Egger, Simple Mode, and Weighted Mode. We examined the mRNA expressions of Using the IVW model, MR analysis revealed significant causal associations between a reduced risk of colorectal cancer and lowered expressions of AXIN1 (OR=0.866, 95% Lowered expressions of inflammatory protein markers AXIN1, β-NGF, and PD-L1 are causally correlated with a reduced risk of colorectal cancer and their expression levels are associated with TNM staging and tumor differentiation. These markers may thus serve as potential targets for colorectal cancer treatment and prevention. Show less
no PDF DOI: 10.12122/j.issn.1673-4254.2024.07.16
AXIN1